

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 37127/135
412 Rec'd PCT/PTO 06 MAY 1998
U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.5)
09/297668INTERNATIONAL APPLICATION NO
IL97/00353INTERNATIONAL FILING DATE
4 NOV 1997PRIORITY DATE CLAIMED
7 NOV 1996

TITLE OF INVENTION

DETERMINATION AND CONTROL OF BIOMOLECULAR INTERACTIONS

APPLICANT(S) FOR DO/EO/US

Jonathan M. GERSTUNJ et. al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a ☒ is transmitted herewith (required only if not transmitted by the International Bureau)
 - b ☐ has been transmitted by the International Bureau.
 - c ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b ☐ have been transmitted by the International Bureau.
 - c ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d ☐ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 18 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment
A **SECOND** or **SUBSEQUENT** preliminary amendment
16. ☐ A substitute specification
17. ☐ A change of power of attorney and/or address letter.
18. ☐ Other items or information

19. The following fees are submitted
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :
Search Report has been prepared by the EPO or JPO \$ 840
International preliminary examination fee paid to USPTO (37 CFR 1.482) \$ 670
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$ 760
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$ 970
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$ 96

CALCULATIONS PTO USE ONLY

ENTER APPROPRIATE BASIC FEE AMOUNT =
670

Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)).
☐ 20
☐ 30

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	32 - 20 =	12	x 18	216	
Independent claims	3 - 3 =		x 78		

Multiple Dependent Claims (check if applicable).
☐

TOTAL OF ABOVE CALCULATIONS = 886

Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable)
☒
443

SUBTOTAL = 443

Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f))
☐ 20
☐ 30
+

TOTAL NATIONAL FEE = 443

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).
☒
40

TOTAL FEES ENCLOSED = 483

Amount to be refunded

\$

charged

\$ 483


☐ A check in the amount of to cover the above fees is enclosed.
☒ Please charge my Deposit Account No. 06-2140 in the amount of \$ 483 to cover the above fees.
A duplicate copy of this sheet is enclosed.
☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No 06-2140 A duplicate copy of this sheet is enclosed

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO

Mark M. Friedman
c/o Anthony Castorina
2001 Jefferson Davis Highway
Suite 207
Arlington, Virginia 22202
Tel: 703-4151581
Fax: 703-4154864

SIGNATURE



Mark M. Friedman

NAME

33,883

REGISTRATION NUMBER

4 MAY 99

DATE

SMALL BUSINESS CONCERN - NEW APPLICATION

Attorney Docket No.: 27/135IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn RE Application of: JONATHAN M. GERSHONI ET AL.

Filed Concurrently Herewith

For: DETERMINATION AND CONTROL OF BIOMOLECULAR INTERACTIONSVERIFIED STATEMENT UNDER 37 CFR 1.27
CLAIMING STATUS AS A SMALL ENTITY

To The Commissioner of Patents and Trademarks:

I hereby declare that:

I am the owner of, or an official empowered to act on behalf of, the small business concern identified below:

Name of Concern: RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD.Address : P.O. BOX 39296, TEL AVIV 61392, ISRAEL

The small business concern identified above, together with its affiliates, employs fewer than 500 persons and qualifies as a small business concern as defined in 37 CFR 1.9(d) for purposes of paying reduced fees under 35 USC § 41(a) and § 41(b) to the Patent and Trademark Office with regard to the above-entitled invention described in the specification filed herewith.

Rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the above entitled invention.

If the rights held by the small business concern are not exclusive, each other party having rights to the invention is listed below, and no rights to the invention are held by any party who could not qualify as a small entity under 37 CFR 1.9(f), namely any person who could not be classified as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Full Name (Party 1) : NONE

Address : _____

Status : ☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

Full Name (Party 2) : _____

Address : _____

Status : ☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

I acknowledge the duty under 37 CFR 1.28(b) to file, in this application, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the issue fee due after the date on which status as a small entity is no longer appropriate.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application and any patent issuing thereon.

x RAMI FINKLER
Name of Person Signing

x _____
Signature

25-APR-99
Date

Capacity of Person Signing: RAMI FINKLER, Ph.D.
President/General Manager

Address of Person Signing : RAMOT

RAMOT
RAMOT, ISRAEL



RAMOT
RAMOT, ISRAEL

510 Rec'd PCT/PTO 06 MAY 1999

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

J. GERSHONI

Serial No.: 09/xxx,xxx

Filed: concurrently herewith

For: DETERMINATION AND CONTROL
OF BIMOLECULAR INTERACTIONS

Examiner:

§ § § § § § § § § §

Group Art Unit:

Attorney
Docket: 27/135

Commissioner of Patents and Trademarks
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Please amend the above-identified application as follows:

In the Claims:

Please cancel claims 1-111 without prejudice.

Please add new claims 112-143 as follows:

112. (New) A phage display library for displaying a continuous complete pepscan of overlapping peptides constructed from at least a portion of a genome of an organism, the library comprising:

- (a) a plurality of fragments of a complete digest of the at least a portion of the genome of the organism; and
- (b) a plurality of phages, each of said plurality of phages containing one of said plurality of fragments of said complete digest, such that each of said plurality

of phages displays a foreign peptide coded by one of said plurality of fragments and such that a plurality of said foreign peptides are overlapping peptides, said plurality of said foreign peptides from said plurality of phages forming the continuous complete pepscan constructed from the at least a portion of the genome of the organism.

113. (New) The library of claim 112, wherein the at least a portion of the genome comprises a plurality of genes.

114. (New) The library of claim 113, wherein said plurality of genes comprises a complete set of all genes in the genome coding for a protein.

115. (New) The library of claim 114, wherein said complete set of genes comprises the entire genome of the organism.

116. (New) The library of claim 113, wherein the organism is a pathogen selected from the group consisting of a virus, a bacterium, a yeast and a parasite.

117. (New) The library of claim 113, wherein said virus is selected from the group consisting of retrovirus species, hepatitis species, influenza species, human papillomavirus, herpes species, RSV (respiratory syncytial virus) and cytomegalovirus.

118. (New) The library of claim 113, wherein said bacterium is selected from the group consisting of *Mycobacterium tuberculosis* and shigella.

119. (New) The library of claim 113, wherein said parasite is selected from the group consisting of plasmodium species, leishmania species, entamoeba species, giardia species, trichomonas species and trypanosoma species.

120. (New) The library of claim 113, wherein each of said plurality of foreign peptides overlaps at least one other of said plurality of foreign peptides by one amino acid residue.

121. (New) The library of claim 113, wherein each of said plurality of fragments is cloned into a phage gene coding for a coat protein, such that said foreign peptide is displayed by said coat protein.

122. (New) The library of claim 121, wherein said plurality of phages are filamentous phages and said coat protein is selected from the group consisting of pIII and pVIII.

123. (New) A vaccine against an organism, the vaccine comprising:

- (a) the library of claim 113; and
- (b) a pharmaceutical carrier.

124. (New) A method for preparing a discontinuous library of a single biological unit of an organism, the method comprising the steps of:

- (a) digesting at least a portion of a genome of the organism to form a plurality of fragments, said portion of said genome coding for the biological unit;
- (b) ligating said plurality of fragments to form at least one ligated fragment; and

- (c) at least partially digesting said at least one ligated fragment to form a plurality of conformational fragments for coding for at least one discontinuous epitope of the single biological unit, thereby forming the discontinuous library.

125. (New) The method of claim 124, wherein the single biological unit is a polypeptide.

126. (New) The method of claim 124, further comprising the steps of:

- (d) providing a display carrier for said plurality of conformational fragments; and
- (e) inserting said plurality of conformational fragments into said display carrier.

127. (New) The method of claim 126, wherein said display carrier comprises a plurality of bacteria and step (e) is performed by inserting each of said plurality of conformational fragments into genetic material in each of said plurality of bacteria.

128. (New) The method of claim 126, wherein said display carrier comprises a plurality of phages and step (e) is performed by inserting each of said plurality of conformational fragments into genetic material of each of said plurality of phages.

129. (New) The method of claim 128, wherein each of said plurality of conformational fragments is cloned into a phage gene coding for a coat protein, such that said foreign peptide is displayed by said coat protein.

130. (New) The method of claim 129, wherein said plurality of phages are filamentous phages and said coat protein is selected from the group consisting of pIII and pVIII.

131. (New) The method of claim 126, wherein said display carrier comprises a eukaryotic expression vector and step (e) is performed by inserting each of said plurality of conformational fragments into said eukaryotic expression vector.

132. (New) The method of claim 124, wherein step (c) is performed until said at least one ligated fragment is completely digested.

133. (New) The method of claim 124, wherein in step (b), at least three of said plurality of fragments are ligated to form each ligated fragment.

134. (New) The method of claim 124, wherein the single biological unit comprises a plurality of proteins.

135. (New) A discontinuous library of a single biological unit of an organism, comprising a discontinuous library prepared according to the method of claim 124.

136. (New) A method for vaccinating a subject against an organism, comprising the steps of:

- (a) preparing a discontinuous library of a single biological unit of the organism according to the method of claim 124;
- (b) placing said discontinuous library in a vaccine carrier; and

- (c) administering said discontinuous library in said vaccine carrier to the subject.

137. (New) A method for preparing a conformational peptide of a discontinuous epitope of a single biological unit of an organism, the method comprising the steps of:

- (a) digesting at least a portion of a genome of the organism to form a plurality of fragments, said portion of said genome coding for the biological unit;
- (b) ligating said plurality of fragments to form at least one ligated fragment;
- (c) at least partially digesting said at least one ligated fragment to form a plurality of conformational fragments for coding for the discontinuous epitope of the single biological unit, thereby forming said discontinuous library;
- (d) inserting said discontinuous library into an expression system; and
- (e) obtaining the conformational peptide from said expression system.

138. (New) The method of claim 137, wherein said expression system comprises a plurality of bacteria, such that step (d) is performed by inserting each of said plurality of conformational fragments of said discontinuous library into genetic material of each of said plurality of bacteria.

139. (New) The method of claim 137, wherein said expression system comprises a plurality of phages and step (d) is performed by inserting each of said plurality of conformational fragments of said discontinuous library into genetic material of each of said plurality of phages.

140. (New) The method of claim 139, wherein each of said plurality of conformational fragments is cloned into a phage gene coding for a coat protein, such that the conformational peptide is displayed by said coat protein.

141. (New) The method of claim 140, wherein said plurality of phages are filamentous phages and said coat protein is selected from the group consisting of pIII and pVIII.

142. (New) A conformational peptide of a single biological unit of an organism, comprising a conformational peptide prepared according to the method of claim 137.

143. (New) A method for vaccinating a subject against an organism, comprising the steps of:

- (a) preparing a conformational peptide of a single biological unit of the organism according to the method of claim 137;
- (b) placing said conformational peptide in a vaccine carrier; and
- (c) administering said conformational peptide in said vaccine carrier to the subject.


REMARKS

Consideration of the above-identified application in view of the amendments above and the remarks following is respectfully requested.

Claims 1-111 are in this case. Claims 1-111 have now been cancelled without prejudice. New claims 112-143 have now been added.

In view of the above new claims and remarks it is respectfully submitted that claims 112-143 are in condition for allowance. Prompt notice of allowance is respectfully solicited.

Respectfully submitted,



Mark M. Friedman
Attorney for Applicant
Registration No. 33,883

Date: May 3, 1999

DETERMINATION AND CONTROL OF
BIMOLECULAR INTERACTIONS

FIELD AND BACKGROUND OF THE INVENTION

The present invention relates to the determination and control of
5 bimolecular interactions and, more particularly, to the exploitation of these
interactions for the production of new pharmaceuticals, such as vaccines, and
diagnostic or research assays, such as antibody-based assays.

Bimolecular interactions are important for a variety of biological
processes, including pathological processes. Such interactions typically involve
10 the recognition of a three-dimensional structure, such as a protein, carbohydrate
or drug ligand, by another such structure. Nature performs with ease many
such interactions, which so far have proven largely refractory to analysis. Such
difficulty has had a negative impact on the fields of vaccine and drug
development in particular, which have had to rely on a trial-and-error
15 approach, in the absence of defined rules for the production of novel vaccines
and other pharmaceuticals. However, such trial-and-error approaches are
costly and inefficient. Clearly, new approaches are needed in these fields.

The problem of vaccine and drug development, which is associated with
bimolecular interactions, can be narrowed to the interaction between specific
20 epitopes on the two molecules involved. In the case of two proteins, these
epitopes can be composed of particular peptides, or of peptides and
carbohydrates. For a drug and its receptor, these epitopes may consist of
peptides on the receptor, and functional groups on the drug. These different
materials would appear to indicate that these different types of bimolecular
25 interactions would require different systems for study. However, as described
below, all of these different epitopes can be mimicked by peptides. Thus, a
single system for screening large numbers of peptides could be employed to
explore all of these different types of epitope interactions, since all of these
interactions could be represented by different types of peptide libraries. For
30 example, peptides which mimic a carbohydrate could be found using a random

peptide library, which contains all possible peptides of a given length. Alternatively, an antigen library could be used to represent peptides derived from the primary sequence of an antigen, such as a protein, for example. If such an antigen library represented all possible peptides of a given length
5 contained within the protein, the library could be said to represent a complete pepscan of the antigen.

Such a complete pepscan could be found in a reference by Baughn et al. [Baughn, R.E., Demecs, M., Taber, L.H. and D.M. Musher, Infection and Immunity, 1996, 64:2457-2466] for the 15-kDa lipoprotein of Treponema
10 pallidum, which causes syphilis. Overlapping decapeptides (ten amino acids) were synthesized, each of which overlapped the next by nine amino acids, and were offset by one amino acid, so that a complete set of decapeptides was obtained. These were then screened with sera from syphilitic rabbits in an ELISA (enzyme-linked immunosorbent assay), to find those peptides which
15 reacted with antibodies against syphilis. The limitations to such an approach are immediately obvious, particularly since the synthesis of such a large number of peptides is both tedious and difficult to manage. Clearly, producing complete pepscans by peptide synthesis limits the approach for small proteins. Indeed, Baughn et al. note that their choice of protein was strongly influenced
20 by size.

Thus, a new approach to the exploration of bimolecular interactions, and by extension to the fields of vaccine and drug development, is required. This approach uses combinatorial phage display peptide libraries to quickly sort through a huge number of peptides to find those peptides of interest, by a
25 screening assay which functionally selects for a particular behavior in a peptide, as described by G.P. Smith and J.K. Scott [Scott, J.K. and G.P. Smith, Science, 1990, 249:386-390 and Smith, G.P. and J.K. Scott, Methods in Enzymol., 1993, 217:228-257]. For example, to find peptides which bind a particular protein, a phage display peptide library can be affinity-purified using
30 that protein, and then reinfected into bacteria to make more phage containing

those peptides of interest. Thus, two problems are solved simultaneously. First, a huge number of peptides can be screened in a single assay. Second, those peptides of interest can be enriched simply by infecting bacteria with the phage containing those peptides, and using the biological machinery of the bacteria to make more phages of interest. Thus, combinatorial phage display peptide libraries can do quickly and easily what artificial laboratory techniques cannot.

Such phage display peptide libraries are typically constructed in the following manner. Phages consist of DNA surrounded by coat proteins, which enable the phage to infect host bacteria and replicate themselves, producing many copies of the phage. To exploit this property, DNA sequences coding for the peptide of interest are inserted into the gene coding for a phage coat protein. As long as these insertions do not interfere with the life cycle of the phage, these modified phages will have coat proteins which display the foreign peptide. Filamentous phages are the preferred vectors, because two of their coat proteins can be easily modified to display foreign peptides, and thus foreign epitopes, on their surface. In general, these modifications are well tolerated. However, even if the modifications are not tolerated, the phage can still be rescued by a variety of techniques, including co-infection with a wild-type phage, known in the art as a helper phage.

The two coat proteins of the filamentous phage of types such as M13, fd and f2 are known as pIII and pVIII. There are only five copies of pIII on the phage coat, while there are about 2700 copies of pVIII on the coat. However, pIII can generally tolerate large insertions of up to a few hundred amino acids in length, while pVIII can tolerate only five or six amino acid insertions. As noted above, other techniques can be used to rescue phage with pVIII proteins containing larger insertions.

There are two divergent methods for selecting the group of peptides which are to be inserted into the phages to form the phage library. The first type of peptide group is selected according to a known DNA or protein

sequence, and forms a series of overlapping peptides. These protein-derived peptides can be used to represent a protein epitope or an entire protein. The second type of peptide group is a partial or complete set of random oligonucleotides. The first group is clearly most useful for a defined problem; for example, the mapping of a particular epitope. The second group is clearly useful when an amino acid sequence for an epitope is unknown, discontinuous in the primary amino acid sequence, or as in the case for complex carbohydrate epitopes, non-existent. In the last case, peptides, called mimotopes, have been found which mimic a selected carbohydrate epitope.

10 The use of each of these groups of peptides can be most easily demonstrated with reference to the field of vaccine development. Vaccinology is based upon the discovery of epitopes within the pathogen of interest which can be used to elicit an immune response which can neutralize that pathogen. Once these epitopes have been found, they can be presented to the immune system as an active vaccine, to prime the immune system against future infection, in most cases, without causing any infection or pathology themselves. Alternatively, antibodies which bind these epitopes can be isolated and administered as a passive vaccine. Thus, vaccinology depends upon the screening of large numbers of epitopes, in the hope of finding such "neutralizing epitopes", and as such is clearly amenable to the phage display library approach.

One example is the screening of random peptide phage libraries with purified antibodies or sera from humans or animals which have been challenged with a particular pathogen or with an antigen of that pathogen. For example, sera from human patients immunized against a hepatitis B viral antigen, an envelope protein from the virus, were used to screen a random library of nonapeptides (peptides of nine amino acids) inserted into the coat protein pVIII. Phages were selected which contained a nonapeptide that was both an antigenic and an immunogenic mimic of the actual viral antigen [Folgori, A. et al., EMBO, 1994, 13:2236-2243]. Such an approach has also been used in diseases

where specific antigens are not known, in an effort to map those antigenic epitopes which react with antibodies in sera which have been raised against the pathogen itself.

The use of protein or antigen derived phage libraries represents a more pathogen-specific approach. The advantage of the antigen derived approach is that the peptides presented by the phage are all related to the pathogen of interest, unlike the random peptide approach, in which many of the peptides will not represent any portion of the pathogen. Thus, a higher proportion of the phages will contain peptides with potentially useful information.

10 An example of the use of antigen derived phage libraries to map an antigen is given by Wang et al. [Wang et al., J. Immun. Methods, 1995, 178:1-12] for the bluetongue virus outer capsid protein VP5. Bluetongue virus infects sheep and cattle. VP5 is a known antigen for this virus and is 526 amino acids in length. The VP5 gene was partially digested using DNAase I,
15 an enzyme which cuts DNA relatively randomly. The resulting DNA fragments were sorted by size, and those of about 100-200 bp were inserted into the phage pIII gene, and expressed in a phage display library. This library was screened with a monoclonal antibody to find those peptides of the VP5 protein which bind to that antibody and two different peptides were found. As
20 estimated by the authors, this library contained about 200 different peptides, including those peptides representing the vector itself. Thus, only about 70 peptides represented the actual antigen. However, in order for every possible peptide of 30-70 amino acids contained within the VP5 protein to be represented, at least 450 different peptides would be required. Thus, this
25 library did not even completely represent a single known antigen with overlapping peptides. A much more extensive library would be needed to represent all overlapping peptides of a given length within the antigen, thus generating a complete pepscan.

Phage libraries do not need to be used simply for mapping epitopes,
30 however. Perham and colleagues [Greenwood, J., Willis, A.E. and R.N.

Perham, J. Mol. Biol., 1991, 220:821-827; and Willis, A.E., Perham, R.N. and D. Wraith, Gene, 1993, 128:79-83] have suggested that peptide epitopes displayed by phage can act as antigens. Discrete peptides obtained from the major surface protein of the malaria parasite Plasmodium falciparum were
5 injected into mice, and were successfully immunogenic, causing specific antibodies to be raised against these discrete peptides. However, the peptides used were few in number, and no suggestion was made that an entire phage library could be used as a vaccine.

An alternative to the use of phages to display peptides which correspond
10 to inserted DNA fragments is to use the DNA fragments themselves in a DNA vaccine. DNA vaccines are, as their name suggests, composed of DNA which can stimulate antigen-specific immunity within an animal. The DNA in question must code for the antigen of interest. Such DNA vaccines include the expression library immunization system (ELI) or naked DNA vaccines. As
15 noted in Ulmer et al. [Ulmer et al., Curr. Op. Immunol., 1996, 8:531-536], naked DNA vaccines have been shown to be effective against influenza virus in animals. A particular bonus of these naked DNA vaccines is that they can elicit cellular as well as antibody responses, which many conventional vaccines cannot.

20 The expression library immunization system (ELI) also uses naked DNA coding for those proteins expressed by a particular pathogen, as described by Barry et al. [Barry et al., Nature, 1995, 377:632-635]. Alternatively, proteins expressed in bacteria have been used to present recombinant proteins to the immune system, as described by Mougneau et al. [Mougneau et al., Science,
25 1995, 268:563-566]. However, both of these methods are somewhat limited in power as compared to complete pepscans, since complete pepscans can cover substantially every possible continuous epitope of a pathogen, while these other methods only present specific proteins from a pathogen. Furthermore, as noted by Barry et al., large amounts of naked DNA were required for immunization.

Phage can also be used to present peptides for non-vaccine related interactions. Random peptide phage libraries have been used to target organs in vivo by Pasqualini and Ruoslahti [Pasqualini, R. and E. Ruoslahti, *Nature*, 1996, 380:364-366]. In their experiments, an entire random peptide phage library was injected into mice, and the mice were sacrificed 1-4 minutes later. Thus, although phage carrying specific peptides successfully targeted particular organs, the time frame did not permit any immunogenic effect to be observed, nor was such a potential effect even mentioned or intended by the authors.

Random peptide phage libraries have an additional advantage over more specific complete pepsans of an antigen. Random phage libraries can be used to map discontinuous epitopes, while a complete pepsan can be used to map continuous epitopes of an antigen, because of the nature of the group of peptides represented. A continuous epitope can be defined as one in which the antigenic residues reside within a short sequence of amino acids, less than from about ten to about fifteen amino acids. This sequence should definitely not be any longer than the length of the average peptide. Thus, only those epitopes which are continuous will be mapped. However, many epitopes have been shown to be discontinuous. These epitopes are composed of peptides derived from different positions in the primary sequence, but which are adjacent in the three-dimensional structure of the protein. An antigen-derived peptide display library of relatively short peptides does not contain peptides which represent these epitopes.

An example of the importance of discontinuous epitopes is in the study of HIV, or human immunodeficiency virus. HIV causes almost invariably fatal disease in humans; so far, no cure or vaccine has been found. An important step in HIV infection is the binding of an HIV envelope protein, gp120, to the T-cell receptor CD4. CD4 may also be important in post-binding events in HIV infection. Indeed, it has been suggested that CD4 changes conformation in response to HIV binding, and that this altered conformation may also be

responsible for post-binding infection events. Thus, the interaction of gp120 with CD4 is a natural target for vaccine design.

Part of the difficulty in finding such a vaccine, however, is that the major neutralizing epitope, the V3 region of gp120, is hypervariable, so that
5 antibodies raised against this region tend to be specific for one type of HIV and not others. Antibodies have been found with much broader specificity, several of which clearly bind to discontinuous gp120 epitopes. Thus, such discontinuous epitopes are obvious targets for mapping, as an aid to vaccine design.

10 As noted above, random peptide phage libraries have been used to map discontinuous epitopes in a variety of systems. Cortese et al. [Cortese et al., Tibtech, 1994, 6:73-80] review a number of discontinuous epitopes which have been found using random peptide phage libraries. However, screening such
15 libraries with sera has not always produced significant results, probably because of the low or incomplete representation of all discontinuous epitopes. In order to overcome this problem, a refinement of the random peptide phage library approach uses constrained peptides, in which amino acids inserted around the random peptide define a particular structure for the peptide to assume, for example a loop structure. However, this approach forces specific structures to
20 be selected, if all random peptides are to be screened. Alternatively, the sequence of the peptide can be held constant, and those surrounding amino acids which determine the structure of the peptide can be varied. In either case, a great deal of the power of random peptide phage libraries, namely the
25 ability to search a broad group of epitopes, is reduced. Thus, more refined discontinuous epitope mapping approaches are clearly needed, which combine the power of random peptide phage libraries with the specificity of antigen-derived phage libraries.

Carbohydrate-protein interactions have also been studied using random peptide phage libraries because of the ability of such libraries to potentially
30 represent discontinuous epitopes of the carbohydrates themselves. These

interactions are important for a number of biological processes, including lymphocyte migration and binding of the hemagglutinin protein of the human influenza virus to erythrocyte glycoproteins, an important step in infection by the virus. However, these interactions have typically been difficult to study, 5 because of the difficulty in synthesizing complex carbohydrate ligands. To solve this problem, peptides can be found which mimic carbohydrate ligands. These peptides are also called "mimotopes" because of their mimicry of the carbohydrate epitopes. For example, Oldenburg et al. [Oldenburg et al., PNAS, 1992, 89:5393-5397] used a random octapeptide (eight amino acid) 10 phage library and screened these phage for the ability of the peptide to bind the carbohydrate-binding protein concanavalin A. A group of peptides were found which bound to the protein, although many of these peptides had no obvious sequence homology.

The interactions of many different molecules with proteins, including 15 carbohydrates and drugs, could be much more easily elucidated if the three-dimensional structure, or tertiary native conformation, of the protein were known. Currently, these structures have generally been determined by using X-ray crystallography. However, as its name suggests, this method requires the protein to be capable of forming usable crystals, which are non-trivial to 20 prepare. Indeed, many proteins do not form satisfactory crystals at all, including the vast majority of membrane-spanning proteins, such as neurotransmitter receptors. To overcome this barrier, a number of attempts have been made to use algorithms to predict the three-dimensional structure of a protein from its primary amino acid sequence, as described in Protein 25 Folding, ed. by N. Jaenicke, p. 167-181, Amsterdam, Holland (1980), or Computer-Assisted Modeling of Receptor-Ligand Interactions, Theoretical Aspects and Applications to Drug Design, ed. by R. Rein and A. Golombek, 1989, Alan R. Liss, New York for example. Commercially available algorithms include those from MSI, United Kingdom, including Quanta, Delphi 30 and Charmm. However, these algorithms have generally failed to adequately

predict the three-dimensional structure of the protein, simply because there are many theoretical structures or conformers to examine, and the rules of protein folding are not completely known.

A compromise between these two approaches has been the use of
5 laboratory experiments to obtain information about the protein itself, which can then be used to place constraints on such protein structure determinations. Such information can be obtained by NMR (Nuclear Magnetic Resonance), which provides information about the interactions of atoms within the protein in the form of distance constraints, although the distances between atoms must
10 be relatively short (less than about 5 Å). However, NMR suffers from lack of specificity; that is, the interactions of too many atoms are all presented simultaneously, making it difficult to decipher the behavior of individual atoms. Furthermore, NMR requires vast amounts of highly purified protein and is also only suitable for water soluble protein.

15 Alternatively, electron diffraction techniques can be used for a small number of proteins, specifically those membrane-spanning proteins which are highly concentrated within the membrane, such as bacteriorhodopsin.

One method which might be more generally applicable was described in a study by E. Haas [E. Haas, Computer-Assisted Modeling of Receptor-Ligand
20 Interactions, Theoretical Aspects and Applications to Drug Design, ed. by R. Rein and A. Golombek, 1989, Alan R. Liss, New York, p. 157-170]. This method uses the interaction of fluorescent dye molecules attached to particular residues within the protein to obtain information about the structure of the protein. However, this method requires that the protein be purified and
25 labelled with dye molecules, which are both non-trivial procedures.

Once these constraints have been obtained, algorithms are available which use this information to predict the three-dimensional structure of a protein, or at the very least to eliminate those theoretical structures which are not compatible with the experimental evidence. Obviously, as the number of
30 constraints is increased, the predictive ability of these algorithms will be

improved correspondingly. Furthermore, it has been noted that longer range distance constraints, or constraints between pairs of residues which are relatively further apart along the primary amino acid sequence, are more useful than short range distance constraints, such as those calculated by NMR [Wako, H. and H. A. Scheraga, *Macromolecules*, 1981, 14:961-969].

Clearly, such algorithms could be improved by finding constraints which both more accurately reflect partial structures of the protein, and which are more easily measured in a laboratory.

There is thus a widely recognized need for, and it would be highly advantageous to have, a system for the discovery of discontinuous epitopes, to be used as vaccines, for drug design, for diagnostic purposes and for the elucidation of three-dimensional protein structure. Specifically, it would be advantageous to have a system to map discontinuous epitopes which is both complete, yet more specific than random phage libraries. It would also be advantageous to develop DNA vaccines which exploit the concept of overlapping peptides and/or discontinuous epitopes in a variety of expression systems. Finally, it would be advantageous to use discontinuous epitopes for preparing antibodies, as components of diagnostic tools, for preparing passive vaccines and for elucidating three-dimensional protein structure.

20 SUMMARY OF THE INVENTION

According to the present invention there is provided a phage display library, including: (a) a plurality of fragments of a substantially complete digest of substantially the entire genome of an organism; and (b) a plurality of phages, each of the phages containing one of the fragments.

25 In the following methods, most of the examples will use DNA, rather than RNA, as the genetic material. It will be appreciated, however, that many of these methods could also be used for RNA, so that the use of the term "DNA" is not intended to be limiting in these examples. The term "genome"

is hereinafter defined as the complete genetic material of an organism, whether that genetic material is DNA or RNA based.

Preferably, the organism is a pathogen selected from the group consisting of a virus, a bacterium, a yeast and a parasite.

- 5 According to further features in preferred embodiments of the invention described below, there is provided a method of preparing a vaccine, including the steps of: (a) preparing a complete pepscan of at least one polypeptide of an organism; and (b) providing a vaccine carrier for the complete pepscan. The vaccine carrier can optionally include a pharmaceutically appropriate buffer.
- 10 Also optionally, the complete pepscan is produced by synthesizing peptides. Alternatively, the complete pepscan is produced by a plurality of bacteria, the peptides are synthesized by the bacteria. Optionally, the vaccine carrier includes a plurality of phages, the peptides are presented by the phages. Preferably, the phages are filamentous phages and each of the peptides is
- 15 presented by a coat protein of the filamentous phages. Most preferably, the coat protein is pVIII or pIII. Also alternatively, the vaccine carrier includes an eukaryotic expression vector and the complete pepscan is presented by the vector to be preferably used as a DNA vaccine in which the peptides are ultimately synthesized by the organism to be vaccinated.

- 20 According to still further features in preferred embodiments of the invention described below, there is provided a method of vaccinating an organism, including the steps of: (a) preparing a vaccine by the above method; and (b) administering the vaccine to the organism.

- According to another embodiment, there is provided a method of
- 25 preparing a discontinuous library of an organism having a genome, including the steps of: (a) at least partially digesting at least a portion of the genome of the organism to form a plurality of fragments, the portion being characterized as representing at least a part of a single biological unit; and
- (b) ligating the fragments to form at least one ligated fragment; and (c) at least
- 30 partially digesting the ligated fragment to form at least one conformational

fragment. Preferably, the biological unit is a polypeptide. Also preferably, the method further includes (d) providing a display carrier for the at least one conformational fragment. More preferably, the display carrier includes at least one bacteria and the at least one conformational fragment is inserted into
5 genetic material within the at least one bacteria. Alternatively, the display carrier includes at least one phage and the at least one conformational fragment is inserted into genetic material within the phage. Preferably, the phage is a filamentous phage, and the at least one conformational fragment is inserted into a gene for a coat protein of the filamentous phage. Most preferably, the coat
10 protein is selected from the group consisting of pIII and pVIII. Alternatively, the display carrier includes an eukaryotic expression vector and the at least one conformational fragment is inserted into the vector. Also provided is a discontinuous library of the genome of an organism, including at least one conformational fragment, prepared according to the above method.

15 According to still further features in the described preferred embodiments, there is provided a method of preparing a conformational peptide, including the steps of: (a) preparing a discontinuous library of an organism according to the above method; (b) inserting the discontinuous library into an expression system; and (c) obtaining the conformational peptide from
20 the expression system. Preferably, the expression system includes at least one bacteria, the discontinuous library is inserted into genetic material of the at least one bacteria. Most preferably, the conformational peptide is obtained from the expression system by isolating the conformational peptide, such that the conformational peptide is at least a partially purified conformational
25 peptide. Alternatively, the expression system includes at least one phage and the discontinuous library is inserted into genetic material of the at least one phage. Also provided is a conformational peptide, including a peptide, the sequence of the peptide being determined by a digestion product of a ligation product of at least two fragments of at least a partial digest of at least a portion
30 of the genome of an organism, the portion representing at least a part of a

single biological unit. Optionally, the peptide is obtained from an expression system, the expression system including the digestion product.

According to yet another embodiment, there is provided a method of preparing a vaccine, including: (a) preparing a discontinuous library according
5 to the above method; and (b) providing a vaccine carrier for the discontinuous library. Optionally, the vaccine can then be administered to an organism to be vaccinated.

According to yet another embodiment, there is provided a method of detecting an antibody for binding at least one discontinuous epitope of a single
10 biological unit of a first organism, including the steps of: (a) preparing a screening library of the first organism; and (b) detecting the antibody for binding the discontinuous epitope by screening the screening library with immune material from a second organism. Optionally, the screening library includes a discontinuous library prepared according to the above method, and
15 the immune material is prepared by administering at least a portion of the single biological unit of the first organism to the second organism. Alternatively, the screening library includes at least a portion of the single biological unit of the first organism and the immune material is prepared by administering a discontinuous library prepared according to the above method
20 to the second organism. This antibody can form part of a passive vaccine, in another embodiment, and the vaccine can be administered to an organism to be vaccinated.

According to yet another embodiment, there is provided a diagnostic tool for detecting an organism, including: (a) an antibody for binding at least one
25 discontinuous epitope of the organism, the antibody being prepared by screening a discontinuous library with immune material to detect the antibody, the discontinuous library including at least one digestion product of at least one ligation product of digestion fragments of at least a portion of the genome of the organism, the portion representing at least a part of a single biological unit;
30 and (b) a detection assay for determining when the antibody is bound to the at

least one discontinuous epitope of the organism. Preferably, the detection assay employs a detection moiety attached to the antibody. Alternatively, the detection assay employs a gradient, and a location of the antibody within the gradient is dictated by the antibody binding to the at least one discontinuous
5 epitope of the organism. Also alternatively, the detection assay employs a chromatograph, and a location of the antibody within the chromatograph is dictated by the antibody binding to the at least one discontinuous epitope of the organism.

According to still further embodiments, there is provided a method for
10 determining a structure of a protein having an identified gene, including the steps of: (a) preparing a conformational peptide of the protein from the gene according to the above method; (b) screening the conformational peptide with a molecule, the molecule being characterized by having an interaction with the protein; (c) determining a sequence of the conformational peptide; and (d)
15 deducing the structure of the protein from the sequence. Preferably, the molecule is an antibody, the antibody is for binding to at least one discontinuous epitope of the protein. Alternatively, the molecule is a ligand, the ligand is for binding to the protein. Also alternatively, the molecule is a mimotope, the mimotope is for binding a mimotope binding site of the protein.

20 According to other embodiments of the present invention, there is provided a filter for determining if a theoretical structure of a protein is non-biological, including: (a) a dipeptide juxtaposition of the protein, the dipeptide juxtaposition being determined by a sequence of a conformational peptide of the protein, the sequence being determined by a digestion product of a ligation
25 product of at least two fragments of at least a partial digest of at least a portion of the genome of an organism, the portion being characterized as representing at least a part of a single biological unit; and (b) an algorithm for comparing the dipeptide juxtaposition to the theoretical structure and for determining if the theoretical structure is non-biological.

Finally, in yet another embodiment, there is provided a method of obtaining an antibody for binding at least one discontinuous epitope of a single biological unit of a first organism, including the steps of: (a) preparing a vaccination library of the first organism; (b) administering the vaccination library to a second organism for producing the antibody; and (c) detecting the antibody for binding at least one discontinuous epitope of the single biological unit of the first organism, according to the above method. Preferably, the vaccination library includes at a least a portion of the single biological unit of the first organism and the screening library is a discontinuous library prepared according to the above method. Optionally, the screening library includes at least a portion of the single biological unit of the first organism and the vaccination library is a discontinuous library prepared according to the above method.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is of both methods and compositions which can be used to analyze and control bimolecular interactions. Specifically, the present invention includes libraries for both continuous and discontinuous pepsans, which are the basis for a number of products and methods, including both passive and active vaccines and tools for diagnosis and structural analysis.

The invention is illustrated by the following examples, which describe the construction of both continuous and discontinuous pepsan libraries, as well as methods and compositions which use these libraries.

Please note that many experimental protocols, which are well known in the art, are used in the following descriptions but are not described in detail. These prior art protocols are described in a number of protocol and text books. One example of such a book is Molecular Cloning by J. Sambrook et al., Cold Spring Harbor Laboratory Press, 1989, which is incorporated by reference as if fully set forth herein for the sole purpose of providing complete descriptions

of well known prior art experimental protocols. A further example is Cell Biology ed. by J.E. Celis, Academic Press Inc., 1994.

Example 1
Methods of Constructing a Continuous Complete Pepscan Library

5 As described in the Background section above, a pepscan includes peptide fragments of a protein or protein(s) of interest. In a complete pepscan, these peptides overlap such that each peptide is offset from the next by one amino acid residue. A pepscan does not need to be limited to a single protein or even a group of proteins. Instead, a pepscan can also be constructed from
10 the entire genome of an organism. Such a pepscan can be described as a continuous pepscan, because it is prepared from peptide fragments which represent continuous epitopes of the primary amino acid sequence of the protein or proteins. A number of methods can be employed to construct such a continuous complete pepscan.

15 One method involves synthesizing peptides, such that each peptide is offset from the next by one residue. These peptides can be synthesized in a variety of ways including, but not limited to, artificial production by a peptide synthesizing machine.

Another method uses the genome of the organism of interest. First, a
20 substantially complete digest of the genome of the organism of interest is prepared, by digesting the genome so that it is cut into fragments as described hereinbelow. Alternatively, a digest of a portion of the genome of the organism of interest can be prepared, such as a portion of the genome coding for a polypeptide, for example. For example, a complete pepscan of a peptide
25 toxin, such as ricin, venoms including, but not limited to, bungarotoxin or bacterial toxins, might be desirable. Thus, although the following description will refer to "the genome of the organism", it should be understood that a portion of the genome of the organism could also be used. To prepare the digest, typically, DNA is digested by an enzyme which cleaves the DNA

strand. For a substantially complete digest of the genome, the enzyme DNAase I is often used. DNAase I cuts DNA relatively randomly; that is, it cuts between any two bases with relatively equal efficiency. When DNAase I is incubated with DNA under appropriate conditions, a collection of fragments of 5 different sizes is obtained which initiate at substantially every single possible base pair. Thus, the genome is represented by DNA fragments which are offset by one base pair. Appropriate conditions are chosen so that a significant fraction of the fragments fall within a desired size range. This collection of fragments is a substantially complete digest of the genome of the organism.

10 Optionally, such a digest could be prepared by mechanical shearing of the DNA. Such mechanical shearing is well known in the art, and can be accomplished by sonication of the DNA, for example. Mechanical shearing has the further advantage of producing fragments of a more homogeneous size, since shearing forces are greatest in the middle of molecules rather than the 15 edges, and larger molecules are more susceptible to shearing than smaller molecules. However, the cleavage sites are still relatively random, since the genome of the organism is broken relatively randomly during extraction from the organism. One disadvantage of sonication is that the temperature can become very high where the ultrasound waves enter the solution, potentially 20 damaging the DNA.

After the digest has been prepared, the fragments are processed so that all fragment ends are blunt ends, if a blunt-ended vector is used (see below). Those fragments which fall within the desired size range are then separated from the collection of fragments. For example, fragments of from about 50 bp 25 to about 150 bp can be separated by size fractionation. Since only a portion of the collection of fragments from the digest fall within the desired size range, the rest of the fragments are not usable, so a much larger quantity of starting genome material is required to obtain a sufficient quantity of fragments of the desired size range.

Next, a plurality of phages is prepared to receive the group of fragments of the desired size range. This is accomplished by modifying a gene of the phage, so that each fragment can be cloned into the phage gene. The product of that gene, a phage protein, will then include a foreign peptide. The sequence of the foreign peptide will depend upon the inserted DNA fragment. Preferably, a gene for a coat protein is used, so that the phage will display the foreign peptide on its outer surface. Typically, filamentous phages are used because they have coat proteins which are easily modified to receive the foreign DNA fragment. The preferred coat proteins are pIII and pVIII. pIII can tolerate insertions of foreign peptides of up to a few hundred amino acids in length, but only five copies of pIII are on the phage coat. About 2700 copies of pVIII are on the phage coat, but pVIII can only tolerate insertions of up to five or six amino acids, unless special rescue methods are used. The choice of a particular coat protein depends upon both the length of the foreign peptide and upon the desired number of copies per phage of the foreign peptide.

Once the particular coat protein has been chosen, the gene is modified to contain a unique blunt end restriction site, preferably at its N terminal region, using methods which are well known in the art. The particular nature of the restriction site depends upon the strain of phage which is used. For example, for the pIII construct of the fUSE5 vector of the filamentous phage fd-tet such a site could be inserted between the two Sfi-1 sites present on the vector [Scott, J.K. and G.P. Smith, Science, 1990, 249:386-390 and Smith, G.P. and J.K. Scott, Methods in Enzymol., 1993, 217:228-257]. However, it is possible to construct many such blunt-ended phage vectors, by manipulating restriction sites so that DNA fragments can be inserted where desired. Alternatively, oligonucleotide linkers can be used to clone the DNA fragments in distinct and unique restriction sites in the vector which are not necessarily blunt-ended.

Finally, the selected fragments from the digest of the genome of the organism of interest are cloned into the appropriately cut phage vector, using

methods which are well known in the art. These phages constitute the phage display library.

A number of factors must be considered in order to ensure that the phage display library contains a complete pepscan of the genome of the organism.

- 5 Such factors relate to the desired size range of the DNA fragment and the size of the genome of the organism.

The probability of DNAase I randomly digesting the genome so that either end of a resulting DNA fragment is in reading frame is 33.3%. Each DNA fragment can ligate in either one or the other orientation with equal
10 probability. Phages containing a DNA fragment which **ends** out of reading frame are not viable as the read-through downstream to the inserted fragment will likely terminate prematurely and will definitely generate an irrelevant peptide, instead of the engineered pIII or pVIII proteins. Phages containing a DNA fragment which **starts** out of reading frame will also probably terminate
15 prematurely due to the appearance of a stop codon.

These factors, when considered collectively, determine that only about one of eighteen, or about five percent of all of the DNA fragments can functionally express relevant peptides. Furthermore, since the DNA fragments must be in reading frame in order to produce a functional peptide, these
20 fragments effectively code for peptides which overlap by about one residue.

One advantage of deriving pepscans from genetic material is that the sequence of the genetic material does not need to be known. As long as DNA is available, it can be digested and expressed in a phage display library, which can include up to from about 10^{10} to about 10^{10} phages. The size limitations
25 of such a library easily accommodate even rather large genomes, including those of viruses, bacteria, yeast and parasites. For example, viruses have genomes of from about 10^3 to about 10^4 bp or more. Bacteria have genomes of about 10^6 bp, yeast about 10^7 bp and parasites from about 10^7 bp to about 10^8 bp or more. The size of the library required to accommodate a complete

pepscan of the genome of an organism can be calculated according to the following formulas.

$$\text{number of peptides} = \frac{\text{genome size}}{3}$$

$$\text{chances of an inserted fragment yielding a viable phage} = \frac{1}{3} * \frac{1}{3} * \frac{1}{2}$$

only $\frac{1}{18}$ will be viable for an approximately single-fold coverage of the

Of the number of phages initially required for insertion of DNA fragments,

5 complete pepsan. Greater coverage, such as from about five- to about ten-fold coverage, is preferable. In any case, a complete pepsan of even the entire genome of a parasite of about 10^8 bp can clearly be accommodated by a single phage display library, since using the above formulas, only about $6 * 10^8$ phages would be required.

10 As an example, consider the production of a complete pepsan of the entire HIV (Human Immunodeficiency Virus) genome, which is about 9000 bp. About 3000 peptides of a desired size range would be required in order to have a peptide starting at substantially every possible residue. However, since only about five percent of the inserted DNA fragments can express a functionally
15 relevant peptide, in order to fully represent 3000 peptides for about one-fold coverage, a library of about 60,000 phages is required, of which only about 3000 phages will be viable. Libraries of up to from about 10^9 to about 10^{10} phages can easily be prepared. Thus, a complete pepsan of the entire genome of HIV can easily be accommodated within such a library.

20 In order to prepare the phage display library for a complete pepsan of the HIV genome, a substantially complete digest of the HIV genome would need to be prepared, as described above. Since HIV is a retrovirus, the

complete HIV RNA would need to be reverse-transcribed into DNA. This DNA would then need to be substantially completely digested as this term is defined above and fragments of the desired size range separated. For example, the DNA could be incubated with DNAase I under appropriate conditions and fragments of from about 75 to about 150 bp could be separated. These fragments would then be cloned into a coat protein gene of an appropriately cut filamentous phage vector, for example the pIII gene of the fUSE5 vector, or a pVIII vector used in conjunction with a helper phage or other method to produce hybrid phages [Greenwood, J., Willis, A.E. and R.N. Perham, J. Mol. Biol., 1991, 220:821-827; and Willis, A.E., Perham, R.N. and D. Wraith, Gene, 1993, 128:79-83]. Now the complete pepscan of the HIV genome is in a phage display library.

Further examples of phage display libraries containing a complete pepscan of the genome of an organism can also be given. For example, the typical bacterial genome is about one million bp, or 10^6 bp. About 3×10^5 peptides of the desired size range would therefore be necessary, so that a library of about 6×10^6 phage would be required for one-fold coverage, of which about five percent would be viable. Such a library could be prepared for Mycobacterium tuberculosis, a bacteria which was previously described in the Background section above, by using the above methods. Alternatively, libraries could be prepared for any bacterium and especially pathogenic bacterium.

Other examples of organisms include yeast, which has a genome of about 10^7 bp. A library of about 6×10^7 phage would be required for a complete pepscan of the yeast genome. As noted above, the preparation of such a library would involve the substantially complete digestion of the yeast genome, and separating DNA fragments of the desired size. These fragments would then be cloned into the desired phage gene, to form the phage display library.

Still other examples of organisms for which such phage display libraries can be constructed include parasites, which typically have genomes of about

100 million bp, or 10^8 bp, as described above. Examples of such parasites are those which cause leishmaniasis, including Leishmania major and L. braziliensis braziliensis. Another example of a parasite is Plasmodium falciparum, which causes malaria. A phage display library of a complete
 5 pepscan of any one of these parasites could be prepared as described above.

Thus, a phage display library could clearly be prepared for a number of organisms, including, but not limited to, viruses including, but not limited to, retrovirus species such as HIV and HTLV, hepatitis species such as Hepatitis A and Hepatitis B, influenza species, human papillomavirus, herpes species
 10 such as herpes simplex, RSV (respiratory syncytial virus) and cytomegalovirus; bacteria including, but not limited to, Mycobacterium tuberculosis, salmonella, staphylococcus species such as Staph. aureus, and shigella; parasites including, but not limited to, plasmodium species such as Plasmodium falciparum, leishmania species such as Leishmania major and L. braziliensis braziliensis,
 15 entamoeba species, giardia species, trichomonas species and trypanosoma species; and yeasts including, but not limited to, Candida albicans.

Example 2

Methods of Constructing a Bacterial Display Complete Pepscan Library

As noted above, a complete pepscan can be displayed in a phage library.
 20 However, phages are not the only display system for a complete pepscan. The basic principles behind such a library can be extended to a bacterial display or expression library.

The first step in preparing a bacterial display library, as in preparing a phage display library, is to substantially completely digest the genome of the
 25 organism of interest, or a portion of the genome of the organism of interest. Such a digest can be prepared according to the methods given in Example 1 above.

In the second step, the fragments from such a digest can be cloned into a vector, such as a phage, a plasmid, a phagmid or a cosmid. Examples of

commercially available prokaryotic vectors include pKK223-3 and pTrc99, both available from Pharmacia Biotech. Such vectors are well known in the art. Although a phage can act as a vector, the phage itself does not display the peptide on its outer coat. Similarly, the other vectors are used only to
5 introduce DNA fragments into the bacteria, but are not themselves used to display the foreign peptides.

Finally, the vector, with the inserted fragments from the digest, is transfected into the bacterial strain of choice. Again, transfection procedures are well known in the art. These bacteria then produce the peptide coded for
10 by the fragment from the digest. These peptides can accumulate within the cell. Alternatively, they can be displayed on the cell wall of the bacteria, for those bacteria which display proteins or peptides on their cell wall. Alternatively and preferably, they can be secreted into the bacterial growth media, from which they can be collected.

15 A bacterial expression library containing a complete pepscan of the genome of an organism could be prepared for any of the organisms noted above, including, but not limited to, viruses including, but not limited to, retrovirus species such as HIV and HTLV, hepatitis species such as Hepatitis A and Hepatitis B, influenza species, human papillomavirus, herpes species
20 such as herpes simplex, RSV (respiratory syncytial virus) and cytomegalovirus; bacteria including, but not limited to, Mycobacterium tuberculosis, salmonella, staphylococcus species such as Staph. aureus, and shigella; parasites including, but not limited to, plasmodium species such as Plasmodium falciparum, leishmania species such as Leishmania major and L. braziliensis braziliensis,
25 entamoeba species, giardia species, trichomonas species and trypanosoma species; and yeasts including, but not limited to, Candida albicans.

Example 3Methods of Constructing an Eukaryotic Display Complete Pepscan Library

As noted in Example 2, bacteria can be used to construct an expression library for a complete pepscan. However, there are some disadvantages to using bacteria or phages, particularly for eukaryotic genomes. First, it is well known in the art that folding of eukaryotic proteins is not always done correctly by bacteria, which could be problematic for a peptide of sufficient length, such as a peptide of greater than about twenty residues. Second, correct post-translational modification of eukaryotic proteins is typically only performed by eukaryotes. Thus, a eukaryotic display complete pepscan library could be used to solve these problems.

Such a library would be constructed in the following way. First, a substantially complete digest of the genome of the organism of interest, or of a portion of the genome of interest, is prepared, as described in Examples 1 and 2 above. Second, the fragments from the digest are cloned into a eukaryotic expression vector. Both such vectors and such methods are well known in the art. For example, commercially available vectors include pSVK 3 and pBPV, both available from Pharmacia Biotech. Finally, the eukaryotic expression vector, with the inserted fragment from the digest, is transfected into an appropriate eukaryotic system. The eukaryotic cell then produces the peptide as part of a conjugate to an eukaryotic protein. This conjugate can accumulate internally, be expressed on the wall of the cell or secreted into the eukaryotic growth media. A particular advantage of such a conjugate is that unlike a bacterial protein, an eukaryotic protein may have limited or no immunogenicity, which may be important if repeated immunization is required.

Examples of such systems include yeast and mammalian cell lines, such as Cos-1, which is an immortal cell line. However, such transfections do not need to be performed only on isolated cells. For example, the eukaryotic expression vector, with the inserted fragment, could be introduced into cells of a whole eukaryote, without first removing those cells from the eukaryote. For

example, the expression vector and inserted fragment could be introduced into macrophages of a horse, or of a human, such that those macrophages would then produce the peptide coded for by the inserted DNA fragment.

An eukaryotic expression library containing a complete pepscan of the
5 genome of an organism could be prepared for any of the organisms noted above, including, but not limited to, viruses including, but not limited to, retrovirus species such as HIV and HTLV, hepatitis species such as Hepatitis A and Hepatitis B, influenza species, human papillomavirus, herpes species such as herpes simplex, RSV (respiratory syncytial virus) and cytomegalovirus;
10 bacteria including, but not limited to, Mycobacterium tuberculosis, salmonella, staphylococcus species such as Staph. aureus, and shigella; parasites including, but not limited to, plasmodium species such as Plasmodium falciparum, leishmania species such as Leishmania major and L. braziliensis braziliensis, entamoeba species, giardia species, trichomonas species and trypanosoma
15 species; and yeasts including, but not limited to, Candida albicans.

Example 4

Methods of Preparing an Active Vaccine from a Complete Pepscan Library and Methods of Vaccinating an Organism with the Vaccine

As noted above in Examples 1-3, there are a number of methods of
20 preparing a complete pepscan library of a protein or proteins, or of a complete genome of an organism. Once such a library has been prepared, it has a number of potential uses, one of which is as a component of an active vaccine.

As described in the Background section above, an active vaccine causes at least one epitope of a first organism to be presented to the immune system
25 of a second organism, which is the organism to be vaccinated. It should be noted, however, that in the case of autoimmune reactions, treatment of cancerous cells, or cells exhibiting inappropriate activity for the stage in the life cycle of the organism, the first and second organisms are effectively the same organism. Thus, the "epitope of the first organism" is actually an epitope

expressed by a cancerous cell or a cell exhibiting inappropriate activity for the stage in the life cycle of the organism. Alternatively, in the case of autoimmune reactions such as myasthenia gravis, lupus or rheumatoid arthritis, the "epitope of the first organism" is normally expressed, but the immune reaction is inappropriate. In any case, the terms "first" and "second" organism are used below for clarity, it being understood that the "first" and "second" organisms can be the same organism.

Thus, since the complete pepscan libraries described in Examples 1-3 cause a peptide from a complete pepscan to be displayed, and since such a peptide constitutes an epitope or a collection of contiguous epitopes of the first organism, clearly these complete pepscan libraries can be used for presenting immunogenic epitopes. An active vaccine can therefore be prepared as follows.

First, a complete pepscan display library is prepared as described in Examples 1-3. The first organism, whose genome, or a portion of the genome, is used for the complete pepscan, can include, but is not limited to, viruses including, but not limited to, retrovirus species such as HIV and HTLV, hepatitis species such as Hepatitis A and Hepatitis B, influenza species, human papillomavirus, herpes species such as herpes simplex, RSV (respiratory syncytial virus) and cytomegalovirus; bacteria including, but not limited to, Mycobacterium tuberculosis, salmonella, staphylococcus species such as Staph. aureus, and shigella; parasites including, but not limited to, plasmodium species such as Plasmodium falciparum, leishmania species such as Leishmania major and L. braziliensis braziliensis, entamoeba species, giardia species, trichomonas species and trypanosoma species; and yeasts including, but not limited to, Candida albicans.

Next, the complete pepscan display library is placed in a vaccine carrier. The vaccine carrier is a pharmaceutical composition, which may include thickeners, carriers, buffers, diluents, surface active agents, preservatives, and the like, all as well known in the art. Pharmaceutical compositions may also include one or more active ingredients such as but not limited to immune-

system stimulating agents, known in the art as adjuvants, and the like in addition to the complete pepscan library. For example, the vaccine carrier can include pharmaceutically appropriate buffers. Alternatively, if a complete pepscan library is prepared according to Example 1, the vaccine carrier can include a plurality of phages which present the peptides of the complete pepscan, preferably filamentous phages. Most preferably, the DNA fragments are inserted into a coat protein of the phage, optionally pIII or pVIII. In this case an adjuvant may not be required as the phages themselves act as immune system stimulants [Greenwood, J., Willis, A.E. and R.N. Perham, J. Mol. Biol., 1991, 220:821-827; and Willis, A.E., Perham, R.N. and D. Wraith, Gene, 1993, 128:79-83].

Optionally, if a complete pepscan library is prepared according to Example 2, the DNA fragments are inserted into genetic material of the bacteria, so that the complete pepscan can be produced by a plurality of bacteria which synthesize the peptides of the pepscan. Since bacteria themselves are both highly immunogenic, as well as potentially hazardous to administer directly to the organism to be immunized, substantially only the synthesized peptides should be included in the vaccine carrier. Preferably the peptides are cloned as conjugates to a secreted bacterial protein, to facilitate purification. These conjugates are then collected from the bacterial growth media and purified from other media constituents. Proper selection of the bacterial protein can eliminate the need for an adjuvant, as the bacterial protein itself can act as the adjuvant.

Also optionally, if a complete pepscan library is prepared according to Example 3, the vaccine carrier can include the eukaryotic expression vector itself, so that the complete pepscan is presented by the vector. The method of Example 3 can be somewhat modified, in the following manner. Instead of transfecting eukaryotic cells with the eukaryotic expression vector containing the inserted DNA fragment, the eukaryotic expression vector itself can be placed in the vaccine carrier. The combination of the eukaryotic expression

vector and the vaccine carrier is an example of a "naked DNA vaccine", as described in the Background above.

Once the vaccine has been prepared according to one of the above methods, it can be administered to an organism in a number of ways, which are well known in the art. For example, administration may be done topically (including ophthalmically, vaginally, rectally, intranasally), orally, by inhalation, or parenterally, for example by intravenous drip or intraperitoneal, subcutaneous, or intramuscular injection.

Formulations for topical administration may include but are not limited to lotions, ointments, gels, creams, suppositories, drops, liquids, sprays and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.

Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, sachets, capsules or tablets. Thickeners, diluents, flavorings, dispersing aids, emulsifiers or binders may be desirable.

Formulations for parenteral administration may include but are not limited to sterile aqueous solutions which may also contain buffers, diluents and other suitable additives.

Dosing is dependent on responsiveness of the immune system of the organism to be vaccinated, but will normally be an initial dose of the vaccine. If necessary a booster dose or doses can be administered at a later date to achieve a desired level of protection against the first organism, as measured by antibody titer, for example. Persons of ordinary skill in the art can easily determine optimum dosages, dosing methodologies and repetition rates.

Examples of organisms to which such a vaccine could be administered include, but are not limited to, humans, pets such as dogs and cats, farm animals such as horses, pigs, sheep, cattle (both beef and dairy) and goats, laboratory animals such as mice, rats, monkeys and rabbits, and wild animals in captivity such as elephants, lions, tigers and bears, and other mammals, fish

including, but not limited to, trout, salmon, carp and tuna, and birds, including, but not limited to, poultry such as chickens and turkeys, ducks and geese.

Example 5
Methods of Preparing a Discontinuous Library

5 The methods of Examples 1-4 all describe methods of preparing and using complete pepscan display libraries. However, the libraries prepared according to Examples 1-4 all contain continuous pepscans. That is, the DNA fragments code for a continuous peptide, which represents a faithful primary conformation of a fragment of the antigen or epitope. However, as noted in
10 the Background section above, many epitopes are discontinuous. In order to display these epitopes in a library, a different library, referred to herein as a discontinuous library, is required.

A discontinuous library can be prepared as follows. First, a digest of the genetic material of a single biological unit or a portion thereof is prepared,
15 by cutting at least a portion of the genome of an organism into fragments. This portion of the genome should represent at least a portion or part of a single biological unit of the organism. The single biological unit preferably has a discrete biological function.

The digest of the genetic material is preferably substantially complete,
20 such that DNA fragments initiate at substantially every possible base pair. Alternatively, it can be a partial digest, such that DNA fragments initiate at a subset of substantially every possible base pair. In either case, an enzyme can be used to perform the digest. For a substantially complete digest of the DNA, the enzyme DNAase I is often used. As noted for Example 1, DNAase I cuts
25 DNA relatively randomly; that is, it cuts between any two bases with relatively equal efficiency. When DNAase I is incubated with DNA under appropriate conditions, a collection of fragments is obtained which initiate at substantially every single possible base pair. This collection of fragments is a substantially complete digest of the genome of the organism.

123456
1 GAATTC
2 CTTAAG

15 Optionally, either a substantially complete or a partial digest could be prepared by mechanical shearing of the DNA. Such mechanical shearing is well known in the art, and can be accomplished by sonication of the DNA, for example.

The ligation product is then digested again to form DNA fragments, 30 which are then preferably sorted by size to separate those fragments which fall

within the desired size range. Preferably this size range is larger than the size range from the first digest. Similarly to the first digest, this second digest can either be partial or substantially complete, and can be performed according to a variety of methods, including but not limited to, enzymatic and mechanical.

- 5 If a substantially complete digest is desired, DNAase I can be used, by incubating the ligation product with DNAase I under appropriate conditions, in order to obtain at least one DNA fragment. If a partial digest is desired, again restriction enzymes such as EcoRI, SauIII A or even DNAase I can be used under the appropriate conditions, as described above. Alternatively,
- 10 mechanical shearing can be used, by sonication of the ligation product for example. In any case, if desired, DNA fragments which fall within a desired size range can be separated from the rest of the digest.

Each of such DNA fragments is a conformational fragment; that is, a fragment which is potentially capable of representing a discontinuous epitope.

- 15 As noted above, a discontinuous epitope includes the novel contiguous presentation of two different amino acid sequences which were previously discontinuous in the original primary amino acid sequence. The discontinuous library includes the DNA fragment or fragments obtained from this second digestion, whether partial or substantially complete. Optionally, the
- 20 discontinuous library can include a display carrier for the DNA fragment or fragments. Preferably, the display carrier includes one of several optional components and is prepared according to one of several preferred methods as described hereinbelow.

- Preferred Method 1: One optional component is a plurality of bacteria, so that
- 25 the DNA fragment or fragments are inserted into genetic material of the bacteria, according to Example 2.

Preferred Method 2: Another optional component is a plurality of phages, so that the DNA fragment or fragments are inserted into genetic material of the phages, according to Example 1.

Preferred Method 3: Yet another optional component is a eukaryotic expression vector, so that the DNA fragments are inserted into the expression vector, according to Example 3. Optionally, the eukaryotic expression vector can be transfected into eukaryotic cells, according to Example 3.

5 The number of components within the display carrier which are required for a substantially complete representation of a single biological unit in a discontinuous library depend upon a number of factors, such as the type of display carrier, the number of DNA basepairs required to represent the single biological unit, the size of fragments desired from both digests, the extent of
10 both digests and the extent of ligation. However, since the single biological unit typically requires fewer DNA basepairs for representation than a substantially complete genome, clearly a single biological unit could be accommodated by a single library.

 The advantage of the discontinuous library is that it can represent
15 discontinuous epitopes, as noted above. However, in order to reduce the production of illogical or artifactual, biologically irrelevant "epitopes", the genetic material used to produce the library must represent at least a portion of a single biological unit with a biological function. Examples of such biological units include, but are not limited to, a protein, a group of proteins such as a
20 cytoskeleton, and non-protein structures such as a tRNA, ribozymes or a telomere.

 The preparation of a discontinuous library for a protein or a portion of a protein would thus give information about dipeptide juxtapositions within that protein or portion of protein. These dipeptide juxtapositions arise during
25 folding of the protein into its three dimensional structure, when a peptide from one location on the primary amino acid chain is folded next to another peptide from a completely different location on the primary amino acid chain. An epitope taken from the primary amino acid chain which faithfully represents the primary conformation of the protein could never represent such a dipeptide
30 juxtaposition.

Similarly, a discontinuous library could also give information about dipeptide juxtapositions within a group of proteins or quaternary structure, such as a cytoskeleton. The cytoskeleton is composed of a number of different proteins, including tubulin and actin. Since tubulin and actin are completely different proteins, a single epitope from the primary amino acid chain of either protein could never represent a dipeptide juxtaposition of both proteins. However, a discontinuous library prepared from the genes encoding both proteins could represent such dipeptide juxtapositions. Indeed, a discontinuous library could even give information about transient interactions of two or more proteins, such as the binding of gp120 to CD4, for example.

Also, a discontinuous library could be used to represent non-protein structures such as a tRNA, ribozymes or a telomere. A tRNA and a ribozyme are RNA molecules folded into three dimensional structures, while a telomere is the DNA at the ends of a chromosome, which also assumes a particular structure. Since the discontinuous library includes genetic material, such as DNA or RNA, prepared according to the above method, clearly the structure of the telomere itself could be examined using the discontinuous library. The RNA could also be prepared by taking the DNA which codes for the tRNA, preparing a discontinuous library as described above, and then making RNA from the DNA, using in vitro transcription methods well known in the art.

Example 6

Methods of Preparing an Active Vaccine from a Discontinuous Library and Methods of Vaccinating an Organism with the Vaccine

As noted above in Example 5, there are a number of methods of preparing a discontinuous library. Once such a library has been prepared, it has a number of potential uses, one of which is as a component of an active vaccine.

As described in the Background section above, an active vaccine causes at least one epitope of a first organism to be presented to the immune system of a second organism, which is the organism to be vaccinated.

Thus, since the discontinuous libraries described in preferred 5 embodiments of Example 5 can cause a discontinuous or discontinuous epitope of an organism to be displayed, clearly these discontinuous libraries can be used to cause immunogenic epitopes to be displayed. An active vaccine can therefore be prepared as follows.

First, a discontinuous library is prepared as described in Example 5, 10 preferably with a display carrier. The first organism, whose genome is used for the discontinuous library, can include, but is not limited to, viruses including but not limited to retrovirus species such as HIV and HTLV, hepatitis species such as Hepatitis A and Hepatitis B, influenza species, human papillomavirus, herpes species such as herpes simplex, RSV (respiratory 15 syncytial virus) and cytomegalovirus; bacteria including, but not limited to, Mycobacterium tuberculosis, salmonella, staphylococcus species such as Staph. aureus, and shigella; parasites including, but not limited to, plasmodium species such as Plasmodium falciparum, leishmania species such as Leishmania major and L. braziliensis braziliensis, entamoeba species, giardia species, trichomonas 20 species and trypanosoma species; and yeasts including, but not limited to, Candida albicans.

Next, the discontinuous library is placed in a vaccine carrier. The vaccine carrier is a pharmaceutical composition, which may include thickeners, carriers, buffers, diluents, surface active agents, preservatives, and the like, all 25 as well known in the art. Pharmaceutical compositions may also include one or more active ingredients including, but not limited to, immune-system stimulating agents and the like in addition to the discontinuous library. For example, the vaccine carrier can include pharmaceutically appropriate buffers.

Alternatively, if a discontinuous library is prepared according to Preferred 30 Method 1 of Example 5, the vaccine carrier can include a plurality of phages,

preferably filamentous phages. Most preferably, the DNA fragments are inserted into a gene for a coat protein of the phage, optionally pIII or pVIII.

Optionally, if a discontinuous library is prepared according to Preferred Method 2 of Example 5, the DNA fragments are inserted into genetic material of the bacteria, so that the complete pepscan can be produced by a plurality of bacteria which synthesize the peptides of the pepscan as part of a conjugate to a bacterial protein. Since bacteria themselves are both highly immunogenic, as well as potentially hazardous to administer directly to the organism to be immunized, substantially only the conjugates should be included in the vaccine carrier. These conjugates can be allowed to accumulate in the bacterial cell, but preferably include a secreted bacterial protein so that the conjugate is secreted by the bacteria, to facilitate collection of the conjugate from the growth media.

Also optionally, if a discontinuous library is prepared according to Preferred Method 3 of Example 5, the vaccine carrier can include the eukaryotic expression vector itself. Preferred Method 3 of Example 5 can be somewhat modified, in the following manner. Instead of transfecting eukaryotic cells with the eukaryotic expression vector containing the inserted DNA fragment, the eukaryotic expression vector itself can be placed in the vaccine carrier. The combination of the eukaryotic expression vector and the vaccine carrier is an example of a "naked DNA vaccine", as described in the Background above.

Once the vaccine has been prepared according to one of the above methods, it can be administered to the organism to be vaccinated in a number of ways, which are well known in the art. For example, administration may be done topically (including ophtalmically, vaginally, rectally, intranasally), orally, by inhalation, or parenterally, for example by intravenous drip or intraperitoneal, subcutaneous, or intramuscular injection.

Formulations for topical administration may include but are not limited to lotions, ointments, gels, creams, suppositories, drops, liquids, sprays and

powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.

Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, sachets, capsules or
5 tablets. Thickeners, diluents, flavorings, dispersing aids, emulsifiers or binders may be desirable.

Formulations for parenteral administration may include but are not limited to sterile aqueous solutions which may also contain buffers, diluents and other suitable additives.

10 Dosing is dependent on responsiveness of the immune system of the organism to be vaccinated, but will normally include an initial dose of the vaccine. If necessary a booster dose or doses can be administered at a later date to achieve a desired level of protection against the first organism, as measured by antibody titer, for example. Persons of ordinary skill in the art can easily
15 determine optimum dosages, dosing methodologies and repetition rates.

Examples of organisms to which such a vaccine could be administered include, but are not limited to, humans, pets such as dogs and cats, farm animals such as horses, pigs, sheep, cattle (both beef and dairy) and goats, laboratory animals such as mice, rats, monkeys and rabbits, and wild animals
20 in captivity such as elephants, lions, tigers and bears, and other mammals, fish such as trout, salmon, carp and tuna, and birds such as poultry, including chickens and turkeys, ducks and geese.

Example 7 Methods of Preparing a Conformational Peptide

25 A conformational peptide is a peptide which represents a discontinuous epitope, as described in the Background section above. Such a peptide can be prepared by first preparing a discontinuous library, according to the method of Example 5. Second, the discontinuous library is inserted into an expression

system, which synthesizes the peptide. Examples of such an expression system include, but are not limited to, viral, bacterial, eukaryotic, and artificial.

A phage display system can be prepared as follows. First, the discontinuous library can be cloned into the phage. Since the discontinuous library of this embodiment is actually at least one DNA fragment, at least one phage is prepared to receive the at least one fragment. This is accomplished by modifying a gene of the phage, so that the fragment can be cloned into the phage gene. The product of that gene, a phage protein, will then include a foreign peptide. The sequence of the foreign peptide will depend upon the inserted DNA fragment. Preferably, a gene for a coat protein is used, so that the phage will display the foreign peptide on its outer surface. Typically, filamentous phages are used because they have coat proteins which are easily modified to receive the DNA fragment. The preferred coat proteins are pIII and pVIII. pIII can tolerate insertions of foreign peptides of up to a few hundred amino acids in length, but only five copies of pIII are on the phage coat. About 2700 copies of pVIII are on the phage coat, but pVIII can only tolerate insertions of five or six amino acids, unless special rescue methods are used. The choice of a particular coat protein depends upon both the length of the foreign peptide and upon the desired number of copies of the foreign peptide.

Once the particular coat protein has been chosen, the gene is modified to contain a unique blunt end restriction site, preferably at its N terminal region, using methods which are well known in the art. The particular nature of the restriction site depends upon the strain of phage which is used. For example, for the pIII construct of the fUSE5 vector of the filamentous phage fd-tet such a site could be inserted between the two Sfi-1 sites present on the vector. However, it is possible to construct many such blunt-ended phage vectors, by manipulating restriction sites so that DNA fragments can be inserted where desired. Alternatively, oligonucleotide linkers can be used to

clone the DNA fragments in distinct and unique restriction sites in the vector which are not necessarily blunt-ended.

Finally, the fragment or fragments from the digest of the ligation product is cloned into the appropriately cut phage vector, using methods which are well known in the art.

A second system is a bacterial expression system. First, the discontinuous library can be cloned into the vector, such as a phage, a plasmid, a phagemid or a cosmid. Such vectors are well known in the art. Although a phage can act as a vector, the phage itself does not display the peptide on its outer coat. Similarly, the other vectors are used only to introduce DNA fragments into the bacteria, but are not themselves used to display the foreign peptides. Since the discontinuous library of this embodiment is actually at least one DNA fragment, at least one vector is prepared to receive the at least one fragment.

Finally, the vector, with the inserted fragment from the digest, is transfected into the bacterial strain of choice. Again, transfection procedures are well known in the art. These bacteria then produce the peptide coded for by the fragment from the digest. These peptides can accumulate within the cell. Alternatively, they can be displayed on the cell wall of the bacteria or secreted into the bacterial growth media, from which they can be collected.

A third expression system is a eukaryotic expression system, which is prepared as follows. The fragment or fragments from the second digest are cloned into a eukaryotic expression vector. Both such vectors and such methods are well known in the art. For example, commercially available vectors include pSVK 3 and pBPV, both available from Pharmacia Biotech. Next, the eukaryotic expression vector, with the inserted fragment from the digest, is transfected into an appropriate eukaryotic system. Again, transfection procedures are well known in the art. These eukaryotic cells then produce the peptide coded for by the fragment from the digest. These peptides can accumulate within the cell. Alternatively, they can be displayed on the cell

wall of the eukaryote or secreted into the eukaryotic growth media, from which they can be collected.

Examples of such eukaryotic systems include yeast and mammalian cell lines, such as Cos-1, which is an immortal cell line. However, such
5 transfections do not need to be performed only on isolated cells. For example, the eukaryotic expression vector, with the inserted fragment, could be introduced into cells of a whole eukaryote, without first removing those cells from the eukaryote. For example, the expression vector and inserted fragment could be introduced into the macrophages of a horse, or of a human, such that
10 those macrophages would then produce the peptide coded for by the inserted DNA fragment.

Furthermore, the continuous peptide itself has a number of uses. For example, the continuous peptide could be used to block a ligand binding to a receptor, such as gp120 binding to CD4. Alternatively, the peptide could act
15 a molecular decoy, by binding a protein or peptide.

Example 8 Methods of Synthesizing and of Detecting an Antibody for Binding a Discontinuous Epitope

As noted above in the Background section, discontinuous and continuous
20 epitopes of a first organism can be bound by antibodies which are produced by the immune system of a second organism, also referred to as the organism to be vaccinated. Methods of detecting antibodies which bind continuous epitopes are well known in the art, and generally involve screening immune material which contains at least one antibody.

25 The immune material which is screened can be prepared by administering a vaccination entity to the second organism. Optionally, the vaccination entity can include at least a portion of the single biological unit of the first organism. Alternatively, the vaccination entity can include a discontinuous library. The discontinuous library can be prepared according to

Example 5, using Preferred Method 1, 2 or 3. Each of these methods results in the preparation of a discontinuous library which is presented by a display carrier, which can also be an expression carrier. The display carrier can be a phage display library, bacterial expression library or an eukaryotic expression library, depending upon the method which is used.

Optionally, the immune material which is screened can include serum with at least one antibody. For example, such serum could be obtained from a human patient who has been infected by, or immunized against, the first organism. Alternatively, such serum could be obtained from an animal, including, but not limited to, a rabbit or a mouse, which has been infected by, or immunized against, the first organism.

Also optionally, the immune material can include polyclonal antibodies. Polyclonal antibodies can be prepared by injecting a rabbit or an animal with a larger blood volume such as a horse, for example, with a substance or substances which provoke an immune response. Such substances can include, but are not limited to, substantially the entire first organism, or whole or partial proteins from the first organism. The rabbit or horse then produces polyclonal antibodies in response to these substances. Such antibodies are called "polyclonal" because they are derived from more than one B-cell clone.

Monoclonal antibodies, on the other hand, bind to only one epitope of the pathogen. Monoclonal antibodies are obtained from hybridomas, which are produced by fusing spleen-derived B cells which secrete a single antibody, with non-antibody-secreting myeloma cells. Such cells can be prepared from mice cells, for example, or by immortalization of human B-cells by EBV (Epstein-Barr virus), for example.

Once the immune material has been prepared, similar methods to those well known in the art can be used to detect antibodies which bind discontinuous epitopes of a single biological unit of the first organism. As a first step, a screening entity is prepared. This screening entity can include a discontinuous library which is prepared according to Example 5, using Preferred Method 1,

2 or 3. Each of these methods results in the preparation of a discontinuous library which is presented by a display carrier. The display carrier can be a phage display library, a bacterial expression library or an eukaryotic expression library, depending upon the method which is used. Alternatively, the screening
5 entity can include at least a portion of the single biological unit which contains the discontinuous epitope of interest. However, the screening entity should not be identical to the vaccination entity.

After the screening entity has been chosen, it is screened with immune material which contains at least one antibody. Such screening can be
10 performed in a number of different ways which are well known in the art, and some of which are described in Molecular Biology of the Cell.

For example, the screening entity can be substantially immobilized on a solid support. Examples of such solid supports include, but are not limited to, porous membranes such as nylon and nitrocellulose, non-porous films such
15 as polypropylene, or plastics. The immune material can then be incubated with the screening entity under appropriate conditions, so that any antibody or antibodies can bind to the appropriate epitope or epitopes, as presented by the screening library [Smith, G.P. and J.K. Scott, Methods in Enzymol., 1993, 217:228-257].

20 Finally, the presence of the bound antibody or antibodies can be detected in a variety of ways, which are well known in the art. For example, the antibody or antibodies can be directly labelled with a substance which acts as a marker for the presence of the antibody or antibodies. Examples of such substances include, but are not limited to, fluorescent dyes or radioactive
25 substances. Alternatively, greater sensitivity can be obtained by using a secondary antibody which can bind to a variety of antibodies. The secondary antibody can be labelled as above. Optionally, an ELISA (enzyme-linked immunoassay) can be used, in which an enzyme, such as alkaline phosphatase, is linked to the secondary antibody. A substrate is incubated with the enzyme,

and a sensitive chemical test is used to detect the presence of the enzymatic product.

Once the antibody has been detected, the antibody can then be obtained from the immune material, by a number of methods which are well known in the art, for example, protein purification methods including, but not limited to, chromatography.

Example 9
Methods of Preparing a Passive Vaccine
and Methods of Vaccinating an Organism with the Vaccine

10 A passive vaccine is one which already contains an antibody or antibodies against a particular epitope or epitopes, as opposed to an active vaccine, which attempts to stimulate the immune system to produce such antibodies. Passive vaccines can be prepared against discontinuous epitopes according to the following procedure. First, at least one antibody which binds
15 at least one discontinuous epitope is detected, as described above in Example 8. Such an antibody can also be synthesized according to the methods given in Example 8.

Next, the antibody is placed in a vaccine carrier, according to Example 4. Examples of organisms to which such a vaccine could be administered
20 include, but are not limited to, those given in Example 4.

Example 10
A Diagnostic Tool for Detecting an Organism
by Using a Conformational Unit

Frequently it is desirable to diagnose the presence of an immune
25 response to a particular organism in a tissue or blood sample, or even in vivo. Such detection can be accomplished by using a conformational peptide which represents an epitope of the organism of interest, putting the immune material which includes at least one antibody, such as the blood or tissue sample, in contact with the conformational peptide, and then by using a detection assay to

detect antibody binding to the conformational peptide. A diagnostic tool which can perform such a diagnosis has many potential biomedical uses, including the detection of organisms including, but not limited to viruses including but not limited to retrovirus species such as HIV and HTLV, hepatitis species such as
5 Hepatitis A and Hepatitis B, influenza species, human papillomavirus, herpes species such as herpes simplex, RSV (respiratory syncytial virus) and cytomegalovirus; bacteria including, but not limited to, Mycobacterium tuberculosis, salmonella, staphylococcus species such as Staph. aureus, and shigella; parasites including, but not limited to, plasmodium species such as
10 Plasmodium falciparum, leishmania species such as Leishmania major and L. braziliensis braziliensis, entamoeba species, giardia species, trichomonas species and trypanosoma species; and yeasts including, but not limited to, Candida albicans. Certainly, such diagnostic tools are known for detecting the presence of HIV for example. However, these tools generally do not rely upon
15 antibodies which have been specifically prepared to bind discontinuous epitopes.

A novel diagnostic tool can be constructed from a conformational peptide representing at least one discontinuous epitope of a single biological unit of the organism of interest, and a detection assay for determining when an antibody
20 is actually bound to the discontinuous epitope. It should be noted that although this description uses a "conformational peptide", it could be extended to include a discontinuous library as described above in Example 5. Both a conformational peptide and a discontinuous library are hereinafter collectively known as a "conformational unit". The conformational peptide is prepared
25 according to one of the methods of Example 7. These detection assays can employ a detection moiety attached to the conformational peptide, a density gradient, or a chromatograph. Such a detection moiety can include fluorescent dyes such as rhodamine or fluorescein. These dyes can be detected by a spectrophotometer, for example.

Density gradients are well known in the art, and are prepared in the following manner. First, a density gradient is prepared by layering materials of different densities within a container, such as a tube. The material with the highest density is substantially near the bottom of the container, while the material with the lowest density is substantially near the top of the container. An example of such a material is a sucrose solution with varying concentrations of sucrose. The higher the concentration of sucrose, the higher the density of the solution.

After the density gradient has been prepared, a solution containing the conformational peptide and antibody or antibodies of interest is placed on top of the material with the lowest density, being careful not to disturb the gradient. The container with the density gradient is then subjected to ultracentrifugation. A conformational peptide which has been bound by an antibody will have a different density, and hence will move to a different layer, as compared to a conformational peptide which has not been bound by such an antibody. Therefore, each will migrate to a different position along the gradient. After ultracentrifugation, the location of the conformational peptide within the gradient can be detected according to methods which are well known in the art.

Yet another example of a detection assay employs a chromatograph. A chromatograph is a device for separating proteins according to some property. For example, proteins can be separated according to their relative solubility by thin-layer chromatography. In this procedure, a sample which includes proteins in solution is applied to a thin layer of absorbent material, such as cellulose or silica gel, which has been attached to a sheet of stiff material such as plastic or glass. At least one solvent is introduced to one edge of the absorbent material. As the solvent front moves through the absorbent material, the proteins are separated according to their relative solubility in the solvent. Alternatively, proteins can be separated by column chromatography, in which a sample which includes proteins in solution is applied to one end of a column containing a

porous solid. Such a porous solid then separates the proteins by size, or by some other property. Clearly, any of these chromatographs could be used to separate a conformational peptide which is bound by an antibody of interest from a conformational peptide which is not so bound.

5 Thus, this diagnostic tool could be used as follows. First, the conformational unit, either conformational peptide or discontinuous library, is incubated with a sample containing an antibody. A sample is simply defined as containing an antibody, including, but not limited to, a portion of tissue or blood and immune material. "Incubated" is simply defined as allowing the
10 sample to come in contact with the conformational unit under conditions which are appropriate for permitting the binding of the antibody to the conformational unit. For example, an appropriate buffer or buffers could be included, and the sample and conformational unit could be maintained at an appropriate temperature. Next, the detection assay, as described above, could be
15 performed to determine when the conformational unit is bound by the antibody.

Example 11

A Diagnostic Tool for Detecting an Organism with an Antibody

Frequently it is desirable to diagnose the presence of a particular organism in a tissue or blood sample, or even in vivo. Such detection can be
20 accomplished by using an antibody or antibodies which bind to at least one epitope of the organism of interest, and then by using a detection assay to detect antibody binding. A diagnostic tool which can perform such a diagnosis has many potential biomedical uses, including the detection of organisms including, but not limited to, viruses including but not limited to retrovirus
25 species such as HIV and HTLV, hepatitis species such as Hepatitis A and Hepatitis B, influenza species, human papillomavirus, herpes species such as herpes simplex, RSV (respiratory syncytial virus) and cytomegalovirus; bacteria including, but not limited to, Mycobacterium tuberculosis, salmonella, staphylococcus species such as Staph. aureus, and shigella; parasites including,

but not limited to, plasmodium species such as Plasmodium falciparum, leishmania species such as Leishmania major and L. braziliensis braziliensis, entamoeba species, giardia species, trichomonas species and trypanosoma species; and yeasts including, but not limited to, Candida albicans. Certainly, 5 such diagnostic tools are known for detecting the presence of HIV for example. However, these tools generally do not rely upon antibodies which have been specifically prepared to bind discontinuous epitopes.

A novel diagnostic tool can be constructed from an antibody for binding at least one discontinuous epitope of a single biological unit of the organism of 10 interest, and a detection assay for determining when the antibody is actually bound to the discontinuous epitope. The antibody is prepared according to Example 8. These detection assays can employ a detection moiety attached to the antibody, a density gradient, or a chromatograph. Such a detection moiety can include fluorescent dyes such as rhodamine or fluorescein. These dyes can 15 be detected by a spectrophotometer, for example.

Density gradients are well known in the art, and are prepared in the following manner. First, a density gradient is prepared by layering materials of different densities within a container, such as a tube. The material with the highest density is substantially near the bottom of the container, while the 20 material with the lowest density is substantially near the top of the container. An example of such a material is a sucrose solution with varying concentrations of sucrose. The higher the concentration of sucrose, the higher the density of the solution.

After the density gradient has been prepared, a solution containing the 25 antibody or antibodies of interest is placed on top of the material with the lowest density, being careful not to disturb the gradient. The container with the density gradient is then subjected to ultracentrifugation. An antibody which has bound a discontinuous epitope will have a different density, and hence will move to a different layer, as compared to an antibody which has not bound 30 such an epitope. Therefore, each will migrate to a different position along the

gradient. After ultracentrifugation, the location of the antibody within the gradient can be detected according to methods which are well known in the art.

Yet another example of a detection assay employs a chromatograph. A chromatograph is a device for separating proteins according to some property.

5 For example, proteins can be separated according to their relative solubility by thin-layer chromatography. In this procedure, a sample which includes proteins in solution is applied to a thin layer of absorbent material, such as cellulose or silica gel, which has been attached to a sheet of stiff material such as plastic or glass. At least one solvent is introduced to one edge of the absorbent material.

10 As the solvent front moves through the absorbent material, the proteins are separated according to their relative solubility in the solvent. Alternatively, proteins can be separated by column chromatography, in which a sample which includes proteins in solution is applied to one end of a column containing a porous solid. Such a porous solid then separates the proteins by size, or by

15 some other property. Clearly, any of these chromatographs could be used to separate an antibody which is bound to a discontinuous epitope of interest from an antibody which is not so bound.

This diagnostic tool could be used as follows. First, the antibody could be incubated with a sample containing at least one discontinuous epitope of the

20 first organism. A sample is simply defined as containing at least one discontinuous epitope of the organism, including, but not limited to, a portion of tissue or blood and immune material. "Incubated" is simply defined as allowing the sample to come in contact with the at least one discontinuous epitope under conditions which are appropriate for permitting the binding of the

25 antibody to the at least one discontinuous epitope. For example, an appropriate buffer or buffers could be included, and the sample and antibody could be maintained at an appropriate temperature. Next, the detection assay is used for determining when the antibody is bound to the at least one discontinuous epitope of the organism.

Example 12Method of Determining a Structure of a Protein with an Identified Gene
and of Preparing a Filter for Such a Structure Determination

As noted in the Background above, the three-dimensional, or tertiary,
5 structure of a protein can provide useful information which can be exploited for
developing new pharmaceuticals such as vaccines or drugs, and for many other
purposes. However, determining such a protein structure can be difficult.
Methods are known in the art which attempt to determine a protein structure
from the primary amino acid sequence, but these methods are not usually very
10 successful, simply because the "rules" for protein folding are not completely
understood. More successful methods place constraints on such protein
structure determinations, by obtaining information about the protein itself.

Such information can be obtained by NMR, which provides information
about the interactions of atoms within the protein, as noted in the Background
15 section above. However, NMR suffers from lack of specificity; that is, the
interactions of too many atoms are all presented simultaneously, making it
difficult to decipher the behavior of individual atoms. Furthermore, NMR
requires large amounts of highly pure protein. A more specific method, using
the interaction of fluorescent dye molecules attached to particular residues, was
20 also described in the Background section above. However, this method
requires that the protein be purified and labelled with dye molecules, which are
non-trivial procedures.

A better method for determining specific interactions between parts of
the protein, and hence for obtaining constraints in the form of a partial
25 structure which can be used to determine the full protein structure, requires
only that the protein has an identified gene. By "identified", it is meant that
the gene is available and that the sequence of the gene is known. This method
is as follows.

First, a conformational peptide of the protein of interest is prepared
30 according to Example 7. Second, the conformational peptide is screened with

a molecule. This molecule is characterized by having a known interaction with the protein of interest. By screening the conformational peptide with the molecule, a conformational peptide which represents a true dipeptide juxtaposition of the protein can be obtained. Methods of screening can include
5 any method which permits detection of the binding of the molecule of interest to the protein itself, simply by substituting the conformational peptide for the protein in the assay.

Next, the amino acid sequence of the conformational peptide is determined. One method of determining the amino acid sequence is to
10 determine the DNA sequence of the conformational fragment which codes for the conformational peptide. Alternatively, the conformational peptide can be directly sequenced, by hand or by machine, according to methods which are well known in the art. This sequence can be used to determine a dipeptide juxtaposition; that is, the two peptides of the protein which form a
15 discontinuous epitope due to their relative locations in the folded protein. Such a dipeptide juxtaposition actually represents a partial structure of the protein, since it gives information about the relative location of two parts of the protein within the three-dimensional structure.

This partial structure can be used as a basis for deducing the
20 substantially complete three-dimensional structure of the protein. For example, the partial structure can be used as a constraint, in order to limit the number of theoretical structures which must be examined. Such a constraint is similar to that derived from the interaction of fluorescent dye molecules attached to particular residues, as described in the Background above. Thus, clearly the
25 general use of such constraints is well known in the art. However, the specific use of a dipeptide juxtaposition is clearly novel and non-obvious.

Furthermore, such a dipeptide juxtaposition can clearly be used as part of a filter for determining if a theoretical structure of a protein is non-biological. Such a filter would include a dipeptide juxtaposition of a protein
30 as described above, and an algorithm for comparing the dipeptide juxtaposition

to the theoretical structure, in order to determine if the theoretical structure is non-biological. Such algorithms are well known in the art, as described above in the Background, and include commercially available algorithms such as Delphi and Charmm. Further references include Havel, T.F. and K.J.
5 Wutrich, J. Mol. Biol., 1985, 182:281-294.

While the invention has been described with respect to a limited number of embodiments, it will be appreciated that many variations, modifications and other applications of the invention may be made.

WHAT IS CLAIMED IS:

1. A phage display library, comprising:
 - (a) a plurality of fragments of a substantially complete digest of substantially the entire genome of an organism; and
 - (b) a plurality of phages, each of said phages containing one of said fragments.

2. The phage display library of claim 1, wherein said organism is a pathogen selected from the group consisting of a virus, a bacterium, a yeast and a parasite.

3. The phage display library of claim 2, wherein said virus is selected from the group consisting of retrovirus species, hepatitis species, influenza species, human papillomavirus, herpes species, RSV and cytomegalovirus.

4. The phage display library of claim 2, wherein said bacterium is selected from the group consisting of Mycobacterium tuberculosis and shigella.

5. The phage display library of claim 2, wherein said parasite is selected from the group consisting of plasmodium species, leishmania species, entamoeba species, giardia species, trichomonas species and trypanosoma species.

- 6. A method of preparing a vaccine, comprising the steps of:
 - (a) preparing a complete pepscan of at least one polypeptide of an organism; and
 - (b) providing a vaccine carrier for said complete pepscan.

7. The method of claim 6, wherein said vaccine carrier includes a pharmaceutically appropriate buffer.

8. The method of claim 6, wherein said complete pepscan is produced by synthesizing peptides.

9. The method of claim 6, wherein said complete pepscan is produced by a plurality of bacteria, said peptides are synthesized by said bacteria.

10. The method of claim 6, wherein said vaccine carrier includes a plurality of phages, said peptides are displayed by said phages.

11. The method of claim 10, wherein said phages are filamentous phages.

12. The method of claim 11, wherein each of said peptides is presented by a coat protein of said filamentous phages.

13. The method of claim 12, wherein said coat protein is selected from the group consisting of pIII and pVIII.

14. The method of claim 6, wherein said vaccine carrier includes an eukaryotic expression vector and said complete pepscan is represented by said vector.

15. A method of vaccinating an organism, comprising the steps of:

- (a) preparing a vaccine by the method of claim 6; and
- (b) administering said vaccine to the organism to be vaccinated.

16. The method of claim 15, wherein said complete pepscan is produced by synthesizing peptides.

17. The method of claim 15, wherein said vaccine carrier includes a plurality of phages, said peptides are displayed by said phages.

18. The method of claim 17, wherein said phages are filamentous phages.

19. The method of claim 18, wherein each of said peptides is presented by a coat protein of said filamentous phages.

20. The method of claim 19, wherein said coat protein is selected from the group consisting of pIII and pVIII.

21. A method of preparing a discontinuous library of an organism having a genome, comprising the steps of:

- (a) at least partially digesting at least a portion of the genome of the organism to form a plurality of fragments, said portion representing at least a part of a single biological unit;
- (b) ligating said fragments to form at least one ligated fragment; and
- (c) at least partially digesting said ligated fragment to form at least one conformational fragment.

22. The method of claim 21, wherein said biological unit is a polypeptide.

23. The method of claim 21, further comprising:

- (d) providing a display carrier for said at least one conformational fragment.

24. The method of claim 23, wherein said display carrier includes at least one bacterium and said at least one conformational fragment is inserted into genetic material within said at least one bacterium. —

25. The method of claim 23, wherein said display carrier includes at least one phage and said at least one conformational fragment is inserted into genetic material within said phage.

26. The method of claim 25, wherein said phage is a filamentous phage.

27. The method of claim 26, wherein said at least one conformational fragment is inserted into a gene for a coat protein of said filamentous phage.

28. The method of claim 27, wherein said coat protein is selected from the group consisting of pIII and pVIII.

29. The method of claim 23, wherein said display carrier includes an eukaryotic expression vector and said at least one conformational fragment is inserted into said vector.

30. A discontinuous library of the genome of an organism, comprising at least one conformational fragment, said at least one conformational fragment being a digestion product of a ligation product of at least two fragments from a digest of a portion of the genome of the organism, said portion representing at least a part of a single biological unit.

31. The discontinuous library of claim 30, further comprising a display carrier for displaying said at least one conformational fragment. —

32. The discontinuous library of claim 31, wherein said display carrier includes at least one bacterium and said at least one conformational fragment is inserted into genetic material of said at least one bacterium.

33. The discontinuous library of claim 31, wherein said display carrier includes at least one phage, said at least one conformational fragment is inserted into genetic material of said at least one phage.

34. The discontinuous library of claim 33, wherein said at least one phage is a filamentous phage.

35. The discontinuous library of claim 34, wherein said genetic material is a gene for a coat protein of said filamentous phage.

36. The discontinuous library of claim 35, wherein said coat protein is selected from the group consisting of pIII and pVIII.

37. The discontinuous library of claim 31, wherein said display carrier is a eukaryotic expression vector, said at least one conformational fragment is inserted into said vector.

38. A method of preparing a conformational peptide, comprising the steps of:

- (a) preparing a discontinuous library of an organism according to the method of claim 21;
- (b) inserting said discontinuous library into an expression system; and
- (c) obtaining the conformational peptide from said expression system.

39. The method of claim 38, wherein said expression system includes at least one bacterium, said discontinuous library is inserted into genetic material of said at least one bacterium.

40. The method of claim 38, wherein the conformational peptide is obtained from said expression system by isolating the conformational peptide, such that the conformational peptide is at least a partially purified conformational peptide.

41. The method of claim 38, wherein said expression system includes at least one phage and said discontinuous library is inserted into genetic material of said at least one phage.

42. The method of claim 41, wherein said at least one phage is a filamentous phage.

43. The method of claim 42, wherein said genetic material is a gene for a coat protein of said filamentous phage.

44. The method of claim 43, wherein said coat protein is selected from the group consisting of pIII and pVIII.

45. A conformational peptide, comprising a peptide, the sequence of said peptide being determined by a digestion product of a ligation product of at least two fragments of at least a partial digest of at least a portion of the genome of an organism, said portion representing at least a part of a single biological unit.

46. The conformational peptide of claim 45, wherein said peptide is obtained from an expression system, said expression system including said digestion product.

47. The conformational peptide of claim 45, wherein said expression system includes at least one phage, said digestion product is inserted into genetic material of said at least one phage.

48. The conformational peptide of claim 47, wherein said at least one phage is a filamentous phage.

49. The conformational peptide of claim 48, wherein said genetic material is a gene for a coat protein of said filamentous phage.

50. The conformational peptide of claim 49, wherein said coat protein is selected from the group consisting of pIII and pVIII.

51. A method of preparing a vaccine, comprising:

- (a) preparing a discontinuous library according to the method of claim 21; and
- (b) providing a vaccine carrier for said discontinuous library.

52. The method of claim 51, wherein said vaccine carrier includes a pharmaceutically appropriate buffer.

53. The method of claim 51, wherein said discontinuous library is produced by a plurality of bacteria, said peptides are synthesized by said bacteria.

54. The method of claim 51, wherein said vaccine carrier includes at least one phage and said discontinuous library is inserted into genetic material of said at least one phage.

55. The method of claim 54, wherein said at least one phage is a filamentous phage.

56. The method of claim 55, wherein said genetic material is a gene for a coat protein of said filamentous phage.

57. The method of claim 56, wherein said coat protein is selected from the group consisting of pIII and pVIII.

58. The method of claim 51, wherein said vaccine carrier includes an eukaryotic expression vector and said discontinuous library is inserted into said vector.

59. A method of vaccinating an organism, comprising:

- (a) preparing a vaccine according to the method of claim 51; and
- (b) administering said vaccine to the organism to be vaccinated.

60. The method of claim 59, wherein said discontinuous library is produced by a plurality of bacteria, said peptides are synthesized by said bacteria.

- 61. The method of claim 59, wherein said vaccine carrier includes at least one phage, said discontinuous library is inserted into genetic material of said at least one phage.

62. The method of claim 61, wherein said at least one phage is a filamentous phage.

63. The method of claim 62, wherein said genetic material is a gene for a coat protein of said filamentous phage.

64. The method of claim 63, wherein said coat protein is selected from the group consisting of pIII and pVIII.

65. The method of claim 59, wherein said vaccine carrier includes an eukaryotic expression vector, said discontinuous library is inserted into said vector.

66. A method of detecting an antibody for binding at least one discontinuous epitope of a single biological unit of a first organism, comprising:

- (a) preparing a vaccination entity, said vaccination entity being selected from the group consisting of a discontinuous library prepared according to the method of claim 21 and at least a portion of the single biological unit of the first organism;
- (b) preparing immune material by administering said vaccination entity to a second organism;
- (c) preparing a screening entity of the first organism, said screening entity being selected from the group consisting of a discontinuous library prepared according to the method of claim 21 and at least a portion of the single biological unit of the first organism, such that said screening entity and said vaccination entity are not identical; and
- (d) detecting the antibody for binding the discontinuous epitope by screening said screening entity with said immune material.

67. The method of claim 66, wherein said immune material includes serum containing at least one antibody.

68. The method of claim 66, wherein said immune material includes a monoclonal antibody.

69. The method of claim 66, wherein said immune material includes polyclonal antibodies.

70. A method of producing a passive vaccine against a first organism, comprising:

- (a) detecting an antibody for binding at least one discontinuous epitope of a single biological unit of the first organism according to the method of claim 66; and
- (b) providing a vaccine carrier for said antibody.

71. The method of claim 70, wherein said immune material includes serum containing at least one antibody.

72. The method of claim 70, wherein said immune material includes a monoclonal antibody.

73. The method of claim 70, wherein said immune material includes polyclonal antibodies.

74. A passive vaccine against a first organism, comprising at least one antibody for binding at least one discontinuous epitope of a single biological unit of the first organism, said antibody being prepared according to the method of claim 66, and a vaccine carrier.

75. The passive vaccine of claim 74, wherein said immune material includes serum containing at least one antibody.

76. The passive vaccine of claim 74, wherein said immune material includes a monoclonal antibody.

77. The passive vaccine of claim 74, wherein said immune material includes polyclonal antibodies.

78. A method of passively vaccinating an organism, comprising administering the passive vaccine prepared according to claim 74 to the organism.

79. A diagnostic tool for detecting a first organism, comprising:

- (a) an antibody for binding at least one discontinuous epitope of a single biological unit of the first organism, said antibody being prepared by screening a screening entity with immune material from a second organism to detect said antibody, said screening entity including at least one digestion product of at least one ligation product of digestion fragments of at least a portion of the genome of the organism, said portion representing at least a part of a single biological unit; and
- (b) a detection assay for determining when said antibody is bound to said at least one discontinuous epitope of the organism.

80. The diagnostic tool of claim 79, wherein said detection assay employs a detection moiety attached to said antibody.

81. The diagnostic tool of claim 79, wherein said detection assay employs a gradient, and a location of said antibody within said gradient is

dictated by said antibody binding to said at least one discontinuous epitope of the organism.

82. The diagnostic tool of claim 79, wherein said detection assay employs a chromatograph, and a location of said antibody within said chromatograph is dictated by said antibody binding to said at least one discontinuous epitope of the organism.

83. A method for determining a structure of a protein having an identified gene, comprising the steps of:

- (a) preparing a conformational peptide of the protein from said gene according to the method of claim 38;
- (b) screening said conformational peptide with a molecule, said molecule being characterized by having an interaction with the protein;
- (c) determining a sequence of said conformational peptide; and
- (d) deducing the structure of the protein from said sequence.

84. The method of claim 83, wherein said molecule is an antibody, said antibody is for binding to at least one discontinuous epitope of the protein.

85. The method of claim 83, wherein said molecule is a ligand, said ligand is for binding to the protein.

86. The method of claim 83, wherein said molecule is a mimotope, said mimotope is for binding a mimotope binding site of the protein.

87. A filter for determining if a theoretical structure of a protein is non-biological, comprising:

- (a) a dipeptide juxtaposition of the protein, said dipeptide juxtaposition being dictated by a sequence of a conformational peptide of the protein, said sequence being determined by a digestion product of a ligation product of at least two fragments of at least a partial digest of at least a portion of the genome of an organism, said portion being characterized as representing at least a part of a single biological unit; and
- (b) an algorithm for comparing said dipeptide juxtaposition to the theoretical structure and for determining if the theoretical structure is non-biological.

88. A method of obtaining an antibody for binding at least one discontinuous epitope of a single biological unit of a first organism, comprising the steps of:

- (a) preparing a vaccination entity of the first organism;
- (b) administering said vaccination entity to a second organism for producing the antibody; and
- (c) detecting the antibody for binding at least one discontinuous epitope of the single biological unit of the first organism, according to the method of claim 66.

89. The method of claim 88, wherein said single biological unit is a polypeptide.

90. The method of claim 88, further comprising providing a display carrier for said discontinuous library.

91. The method of claim 90, wherein said display carrier includes at least one bacterium, said discontinuous library is inserted into genetic material within said at least one bacterium.

92. The method of claim 90, wherein said display carrier includes at least one phage, said discontinuous library is inserted into genetic material within said phage.

93. The method of claim 90, wherein said phage is a filamentous phage.

94. The method of claim 91, wherein said discontinuous library is inserted into a gene for a coat protein of said filamentous phage.

95. The method of claim 92, wherein said coat protein is selected from the group consisting of pIII and pVIII.

96. The method of claim 90, wherein said display carrier includes an eukaryotic expression vector and said discontinuous library is inserted into said vector.

97. A vaccine, comprising a vaccine prepared according to the method of claim 6.

98. The method of claim 97, wherein said vaccine carrier includes a pharmaceutically appropriate buffer.

99. The method of claim 97, wherein said complete pepscan is produced by synthesizing peptides.

100. The method of claim 97, wherein said complete pepscan is produced by a plurality of bacteria, said peptides are synthesized by said bacteria.

101. The method of claim 97, wherein said vaccine carrier includes a plurality of phages, said peptides are displayed by said phages.

102. The method of claim 101, wherein said phages are filamentous phages.

103. The method of claim 102, wherein each of said peptides is presented by a coat protein of said filamentous phages.

104. The method of claim 103, wherein said coat protein is selected from the group consisting of pIII and pVIII.

105. The method of claim 97, wherein said vaccine carrier includes an eukaryotic expression vector and said complete pepscan is represented by said vector.

106. A diagnostic tool for detecting an antibody for binding an epitope of an organism having a genome, comprising:

- (a) a conformational unit, said conformational unit selected from the group consisting of a conformational peptide of the organism prepared according to claim 38 and a discontinuous library of the organism prepared according to the method of claim 21; and
- (b) a detection assay for determining when said conformational unit is bound by the antibody.

- 107. The diagnostic tool of claim 106, wherein said detection assay employs a detection moiety attached to said conformational unit.

108. The diagnostic tool of claim 106, wherein said detection assay employs a gradient, and a location of said conformational unit within said gradient is dictated by the antibody binding to said conformational unit.

109. The diagnostic tool of claim 106, wherein said detection assay employs a chromatograph, and a location of said conformational unit within said chromatograph is dictated by the antibody binding to said conformational unit.

110. A method of detecting an antibody for binding an epitope of an organism having a genome, comprising the steps of:

- (a) incubating said conformational unit of the diagnostic tool of claim 106 with a sample containing the antibody; and
- (b) performing said detection assay of the diagnostic tool of claim 106 for determining when said conformational unit is bound by the antibody.

111. A method of detecting a first organism, comprising the steps of:

- (a) incubating said antibody of the diagnostic tool of claim 79 with a sample containing at least one discontinuous epitope of the first organism; and
- (b) performing said detection assay for determining when said antibody is bound to said at least one discontinuous epitope of the organism.

Combined Declaration For Patent Application and Power of Attorney

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled DETERMINATION AND CONTROL OF BIOMOLECULAR INTERACTIONS, the specification of which (check one) ☒ is attached hereto.

☐ was filed on _____ as Application Serial No. _____ and was amended on _____. I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

<u>IL97/00353</u> (number)	<u>PCT</u> (Country)	<u>4-Nov-97</u> (Day, Month, Year Filed)
<u>119586</u> (number)	<u>IL</u> (Country)	<u>7-Nov-96</u> (Day, Month, Year Filed)
_____ (number)	_____ (Country)	_____ (Day, Month, Year Filed)

Priority Claimed

<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No
<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No
<input type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States Application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

<u>NONE</u> (Application Serial No.)	_____ (Filing Date)	_____ Status (patented, pending, abandoned)
---	------------------------	---

_____ (Application Serial No.)	_____ (Filing Date)	_____ Status (patented, pending, abandoned)
-----------------------------------	------------------------	---

I hereby appoint the following attorneys, with full power of substitution, association, and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

| Mark M. Friedman Registration No. 33,883

Address all Correspondence to:

DR. MARK FRIEDMAN LTD.
c/o ANTHONY CASTORINA
2001 JEFFERSON DAVIS HIGHWAY
SUITE 207
ARLINGTON, VIRGINIA 22202

Direct all telephone calls & faxes to:
ROBERT SHEINBEIN
Phone (703) 415-1581
Fax (703) 415-4864

Attorney Docket: 27/135
page 2 of 2

Continuation of Combined Declaration For Patent Application and Power of Attorney

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statement may jeopardize the validity of the application of any patent issued thereon.

*FULL NAME OF SOLE OR FIRST INVENTOR JONATHAN M. GERSHONI	INVENTOR'S SIGNATURE <i>[Signature]</i>	DATE April 19 99
RESIDENCE HANASI HARISHON 28, REHOVOT 76302, ISRAEL ILX		CITIZENSHIP ISRAELI
POST OFFICE ADDRESS HANASI HARISHON 28, REHOVOT 76302, ISRAEL		

*FULL NAME OF SECOND INVENTOR DAVID ENSHEL	INVENTOR'S SIGNATURE <i>[Signature]</i>	DATE 4/19/99
RESIDENCE LAVI E 8, GIVATAYIM 53326, ISRAEL ILX		CITIZENSHIP ISRAELI
POST OFFICE ADDRESS LAVI E 8, GIVATAYIM 53326, ISRAEL		

*FULL NAME OF THIRD INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP ISRAELI	
POST OFFICE ADDRESS		

*FULL NAME OF FOURTH INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP ISRAELI	
POST OFFICE ADDRESS		

*FULL NAME OF FIFTH INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP ISRAELI	
POST OFFICE ADDRESS		

*FULL NAME OF SIXTH INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP ISRAELI	
POST OFFICE ADDRESS		

*FULL NAME OF SEVENTH INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP ISRAELI	
POST OFFICE ADDRESS		